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Multiple cancer populations frequently report cognitive impairment following 
treatment with chemotherapy agents (“chemo-brain”). Impaired 
neuropsychological performance is commonly reported in cognitive domains of 
attention and executive function. Understanding neural mechanisms underlying 
cognitive impairments is essential to developing prevention and rehabilitation 
strategies. Brain imaging studies frequently show chemotherapy-related 
impairments within the attentional control network, which is comprised of a 
constellation of cortical regions that govern reportedly impaired cognitive 
functions. In the current dissertation research, I developed a novel 
electrophysiology battery aimed at recording near-instantaneous neural activity 
within the attentional control network during cognitive task performance. Cancer 
patients diagnosed with hematological malignancy (e.g. lymphoma, myeloma) 
completed three longitudinal assessments: (1) prior to starting chemotherapy, 
and following (2) one-month and (3) three-months of chemotherapy. Comparison 
groups included patients not receiving chemotherapy and demographically-
matched healthy controls. Outcome measures provide initial support for 
contributions from both tumor biology and chemotherapy toxicity to functional 
changes in attentional control network activity. Furthermore, both cancer groups 
showed evidence for reduced information processing capacity while completing a 
simulation of naturalistic driving behavior. These results provide a unique 
platform for understanding basic neural mechanisms and translational impacts of 
attentional control impairment in cancer patients. Future large-scale studies must 
be committed to confirming these results, and further innovative work is 
necessary to confirm the link between previous brain imaging studies and 
cognitive electrophysiology measures used here. Innovative chemotherapies are 
improving survivorship among cancer patients. Thus, ensuring long-term quality 
of life among our growing cancer survivor population is paramount to achieving 
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INTRODUCTION 
Cancer is a physically, emotionally, and mentally devastating disease that 
will be diagnosed in approximately 1.7 million people in the United States each 
year. Improvements in cancer diagnostics and treatments have improved 5-year 
relative survival from 48.7% in 1975 to 69.3% in 2009. Accordingly, the number 
of cancer survivors is expected to rise from an estimated 14.5 million in 2014 to 
19 million by 2024. As cancer treatments continue to improve survival outcomes, 
long-term quality of life (QoL) is becoming a rapidly emerging public health 
concern among our growing cancer survivor population.  
QoL is typically evaluated with self-assessed symptom severity and 
functional status inventories. In a recent survey of 604 cancer survivors and 
6,166 non-cancer survivors,1 symptom complaints were most prevalent in cancer 
survivors for pain (73.47%, OR=2.12), fatigue (68.58%, OR=1.4), sensory 
neuropathy (60.99%, OR=2.42), and cognitive dysfunction (32.22%, OR=1.78). 
Evaluating QoL using self-assessed inventories, however, requires the logical 
antecedent of having the capacity for being self-aware of dysfunctional states. In 
contrast to subjective self-assessment, gold-standard tools are available for 
measuring objective cognitive function. Current evidence suggests a weak 
relationship between subjective and objective functional assessments,2–6 thus 
bringing into question the construct validity of self-assessments to evaluate 
functional status in cancer survivors. It is therefore critical to adequately 
characterize changes in functional status to ensure long-term QoL in cancer 
survivors. 
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The goal of the current dissertation research was to better understand 
cancer- and chemotherapy-related cognitive impairment in hematological 
malignancies. In the following sections, I first provide a broad review of the 
epidemiology, pathology, and treatment of hematological malignancies. Next, I 
review the symptom burden and importance of symptom management for 
treatment outcomes in hematological malignancies. Next, I review patterns of 
cognitive impairment observed in hematological malignancies, and discuss them 
within the context of biological mechanisms emerging from human and animal 
research. Finally, I discuss the theoretical motivation and empirical goals of the 
current dissertation research.  
Hematological Malignancies 
Epidemiology, Pathology, and Treatment 
 Hematological malignancies are a broad class of blood cancers, including 
lymphoma, myelomas and leukemia. Epidemiological studies have reported that 
1.29 million people in the United States have been diagnosed with a 
hematological malignancy, and will be diagnosed in an estimated 172,910 people 
in 2017.7 Hematological malignancies account for 10.2% of total cancer cases 
and 9.7% of all cancer-related deaths, with 5-year survival approximated at 50%, 
63%, and 73% for myeloma, leukemia, and lymphoma, respectively. 7  
 Pathophysiology underlying hematological malignancies emerges from 
defects in the self-renewal and differentiation of normal hematopoietic stem 
cells8. Normal hematopoietic populations are regulated by self-renewal, 
differentiation, and apoptosis9. In contrast, aberrations in normal hematopoietic 
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stem cells can lead to the production of leukemic stem cells that override 
apoptosis signaling, allowing malignant hematopoietic cells to survive indefinitely.  
Hematological malignancies disrupt two major classes of hematopoietic 
cell lineages: myeloid and lymphoid. Myeloid cells play a major role in innate 
immunity and are involved in inflammatory cytokine secretion10. Malignancies of 
myeloid cells lead to myelodysplasic syndrome (MDS), acute myelogenous 
leukemia (AML), and chronic myelogenous leukemia (CML). Lymphoid cells play 
a major role in both innate and adaptive immunity11,12. Malignancies of lymphoid 
cells lead to lymphomas, lymphocytic leukemias, including acute lymphoblastic 
leukemia (ALL) and chronic lymphocytic leukemia (CLL), and myeloma.  
Treatment for patients diagnosed with hematological malignancies 
typically involves either chemotherapy alone or in combination with 
hematopoietic stem cell transplant (HSCT). Chemotherapy is typically 
administered as a combination of antineoplastic drugs developed to selectively 
interfere with mechanisms of DNA synthesis13–20, DNA repair21–25, and 
immunosuppression26–31 in malignant cells, leading to malignant cell death and 
suppression of the tumor microenvironment. If malignant tumors fail to respond to 
chemotherapy, patients may subsequently undergo a combination of high-dose 
chemotherapy and HSCT. Patients undergoing allogeneic HSCT receive donor 
stem cells following high-dose chemotherapy. Patients undergoing autologous 
HSCT, in contrast, have their own stem cells harvested prior to high-dose 
chemotherapy.   
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Symptom Management and Outcomes 
 Effective symptom management is critical to long-term quality of life. 
Bryant and colleagues32 developed a cancer survivor adaptation model, which 
assumes continuous cognitive appraisal of cancer survivor experiences leads to 
behavioral modifications that moderate disease- and treatment-related changes 
in quality of life. Factor analysis was used to determine how positive (e.g. 
empathy, health awareness, self-esteem) and negative (e.g. anxiety, depression, 
stress) behaviors influenced the relationship between clinical characteristics and 
quality of life, where quality of life was characterized by physical, social, 
emotional, and functional well-being. Quality of life was directly affected by age, 
income, and disease duration, as well as both positive and negative adaptation 
factors. Clinical characteristics indirectly affecting quality of life through both 
positive and negative adaptation were age, gender, race, and undergoing 
treatment. Clinical characteristics indirectly affecting quality of life through 
negative adaptation were education, received chemotherapy, comorbidity, 
psychosocial changes, disease duration, and social support. No clinical 
characteristics indirectly affected quality of life only through positive adaptation. 
Thus, negative, but not positive, behavioral adaptations are more likely to 
contribute to changes in quality of life, suggesting effective symptom 
management must prioritize management of negative behaviors.  
Symptom management is also critical to cancer treatment outcomes. In a 
survival study of 90 older adults (65-89 years old) diagnosed with hematological 
malignancies33, 63% of patients with baseline cognitive impairment survived to 
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one-year follow-up evaluations compared to 88% of patients without baseline 
cognitive impairment. Hazard analyses revealed patients without baseline 
cognitive impairment were 3.3 times more likely to survive during the one-year 
interval. Physical activity has also been associated with improved overall 
survival34–37. These studies highlight the positive impact of physical and cognitive 
function on cancer survival. It is therefore critical to better understand how 
symptom management and functional status influences survival and long-term 
quality of life. For the remainder of this section, symptoms reported in 
hematological malignancies are reviewed.  
 Physical Function. Disease- and treatment-related changes have been 
shown in self-reported measures of physical function38–45, including fatigue, 
exercise, and physical health. Physical health was impaired anywhere from 2 to 
10 years after diagnosis38,40,42,44,45, with frequency analyses showing impairments 
in up to 25% of reporting patients38. Greater changes in physical health were 
found in non-married patients, patients with more comorbidities, and patients 
reporting greater impairments in cognitive health39. Fatigue has been shown to 
be impaired anywhere from 3 months to 5 years after diagnosis.40,41,44 Greater 
changes in fatigue were found in patients who were younger (<50 years), non-
married, progressing in disease stage, reporting greater comorbidities, and 
reporting greater cognitive impairment39,43. Changes in physical function were not 
related to age, gender, race, or education39. Changes in physical function may be 
associated with results from other studies reporting up to 73% of patients 
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engaging in none or some amount of exercise during treatment38, though this 
relationship has not been directly shown.  
 Treatment-related changes in physical function have been mapped out in 
longitudinal studies of NHL and AML patients33,46–48. Prior to treatment, these 
studies found impaired physical function in NHL patients47,48 and normal physical 
function in AML patients46. During treatment, NHL patients reported declines in 
physical function compared to baseline assessments47,48, with low risk (according 
to the age-adjusted International Prognostic Index) patients showing greater 
decline relative to high risk patients47. Physical function was not assessed in AML 
patients during treatment in these studies. Both NHL and AML patients showed 
improvements to baseline levels of physical function, though NHL patients 
reported impaired physical function until 3-months post-treatment46–48. These 
studies suggest physical function in NHL patients is impaired prior to treatment, 
declines during treatment, and returns to (impaired) baseline levels 3-months 
following treatment.  
 Treatment-related changes in fatigue have been mapped out in 
longitudinal studies of AML, NHL, and MDS patients33,46–49. Prior to treatment, 
these studies demonstrated a high prevalence of self-reported fatigue across all 
patient groups33,46–49, with rates of 100%46, 65%49, and 40%33 in AML, AML/MDS, 
and broad patient groups, respectively. During treatment, 79% of AML/MDS 
patients reported clinically significant fatigue49; NHL patients reported significant 
increases in fatigue symptoms relative to baseline measurements47,48, with low 
risk patients showing greater susceptibility to treatment-related increases in 
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fatigue47. Following treatment, 85% of AML patients reported fatigue 12-months 
post-treatment46; fatigue symptoms returned to baseline levels as early as two 
weeks in NHL patients47,48, with high risk NHL patients more likely to return to 
baseline levels than low risk NHL patients47.  
Emotional Function. Disease- and treatment-related factors have been 
associated with self-reported changes in emotional function38–41,43,44. Pathological 
changes in mood symptoms, such as depression and anxiety, are reported under 
the umbrella of emotional function. Changes in emotional function may emerge 
from either individual contributions from, or interactions between, the 
psychological impact of cancer diagnosis or biological impact of treatment50,51. 
Emotional function has been evaluated in hematological malignancy patients 
using a brief questionnaire that assesses general changes in mood38,40,41,44, 
anxiety38,39, or depression38–40. Following diagnosis, changes in mood, anxiety, or 
depression have been reported in up to 25%38, 20%38,39, and 16%38,39, 
respectively. Anxiety symptoms have been associated with younger age, non-
married marital status, and lower subjective cognitive function39,43. Depression 
symptoms have been associated with younger age, non-married marital status, 
disease progression, greater number of comorbidities, and lower subjective 
cognitive function39. Engaging in exercise-related activities has been associated 
with lower prevalence of anxiety and depression.38 Studies failing to find changes 
in emotional function compared patients receiving chemotherapy to those not 
receiving chemotherapy52,53, suggesting changes in emotional function are likely 
due to disease-related tumor burden or psychological trauma rather than 
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treatment toxicity. More complex disease-related emotional traumas, such as 
post-traumatic stress disorder (PTSD), impose longer lasting emotional burden 
on patients. An estimated 39% of hematological malignancy patients reported 
PTSD symptoms up to 10-years post-diagnosis54, where greater PTSD 
symptoms were observed in patients who were younger, non-white, less 
educated, made less than $30,000 annually, underwent stem cell transplant or 
biologic treatment, and still had active disease.  
Treatment-related changes in emotional function have been mapped out 
in longitudinal studies of AML, CML, and NHL patients33,46–48,55. Prior to 
treatment, AML46 and NHL47,48 patients showed at least minor impairments in 
emotional function, with high risk NHL patients more likely to show impairment47 
and 16% of patients across multiple hematological malignancies showing 
impairment33. During treatment, emotional function of NHL patients either 
remained stable or improved47 relative to baseline, whereas 33.3% of CML 
patients demonstrated treatment-related increases in depression symptoms 
relative to baseline55. Following treatment, emotional function of AML patients 
improved46; NHL patients remained stable at 14 days48 and showed improvement 
after 3 months47,48.  
Cognitive Function. Higher-level mental functions, such as thinking, 
memory, and concentration, are critical skills that show well-documented 
disease- and treatment-related changes across multiple cancer types56–59. 
Outside of gold-standard neuropsychological testing, these functions are typically 
evaluated using self-assessment tools that ask patients to rate their own level of 
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cognitive performance. Changes in mental functions have been demonstrated 
across multiple studies39–45,53, with assessments occurring anywhere from 3-
months41 to 10-years45 post-diagnosis. Approximately 32% of patients have 
reported impaired mental function compared to 7% of healthy controls43. 
Complaints of impaired mental function were most common in patients who were 
younger, non-married, and reported greater number of co-morbid conditions39. 
Scores on mental function assessments were correlated with physical health 
competence, mental health competence, anxiety, depression, and fatigue39. As 
discussed below, these tools are weakly related to objective measures of 
cognitive function, suggesting self-assessment of cognitive function may be more 
related to psychosocial factors than cognitive function per se. 
Treatment-related changes in cognitive function have been mapped out in 
longitudinal studies of AML and NHL patients46–48. Prior to treatment, AML46 and 
NHL48 patients reported no cognitive symptoms, though high risk NHL patients 
were more likely to report cognitive symptoms than low risk NHL patients48. 
During treatment, NHL patients reported no changes in cognitive symptoms with 
respect to baseline reports47,48. Following treatment, AML46 and NHL47,48 patients 
reported no changes in cognitive symptoms with respect to baseline, suggesting 
these patients were unaware of any disease- or treatment-related changes in 
cognitive function.  
 Role Function. The goal of promoting effective symptom management is 
to ensure patients are returning to and maintaining their societal roles during and 
following treatment, thus minimizing disease- and treatment-related public health 
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impact. Here, changes in role function are broadly defined as changes in 
activities of daily living, such as social function, employment, and independence. 
Importantly, these complex skills are attributable to physical, emotional, and 
cognitive functions described above. Changes in role functions have been noted 
in several studies33,44,60–63, though most of these studies have focused on 
changes in employment60–63. In a series of studies, Horsboel and colleagues61–63 
examined changes in employment status in patients up to 9 months after being 
diagnosed with hematological malignancy. Patients were examined with respect 
to changes in sick leave61, disability pension62, and work subsidized 
employment63: (1) 54% of patients were on sick leave, with a prevalence of 
depressive symptoms reported in 40% of sick leave patients compared to 15% of 
working patients61; (2) 40% of patients were on disability pension, and relative 
risk assessments revealed myeloma and lymphoma patients were 22.1 and 5.1 
times more likely, respectively, to be on disability pension compared to healthy 
controls62; (3) 17% of patients were on work subsidized employment, and relative 
risk assessments revealed myeloma and CML patients were 13.4 and 13.8 times 
more likely, respectively, to be on work subsidized employment compared to 
healthy controls63. In a separate study of NHL survivors surveyed 8-years post-
diagnosis60, approximately 70% of survivors were unemployed, and 41% of 
survivors indicated they had changed jobs, reduced the number of work hours, or 
stopped working entirely. Furthermore, working survivors reported better mental 
well-being than non-working survivors, and having received chemotherapy 
treatment was associated with lower psychological and social well-being.  
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 Treatment-related changes in role function have been mapped out in 
longitudinal studies of AML and NHL patients46–48. Prior to treatment, AML46 and 
NHL47,48 patients reported impairments in role function, with high risk NHL 
patients more likely to report role function impairments47. During treatment, NHL 
patients reported declines in role function relative to baseline measurements47,48, 
and low risk patients were more likely to report declines in role function 
compared to high risk NHL patients47. Following treatment, AML patients 
remained impaired in role function46, and NHL patients remained impaired after 
14 days48 then returned to baseline levels of role function after 3 months47,48. 
Treatment-related changes in social function have been mapped out in 
longitudinal studies of AML and NHL patients46–48. Prior to treatment, AML46 and 
high-risk NHL47 patients reported impairments in social function; in contrast, low-
risk NHL47 patients and an independent sample of NHL patients reported no 
impairments in social function48. During treatment, NHL patients reported no 
change in social function47,48. Following treatment, AML patients continued to 
experience impairments in social function and NHL patients experienced no 
difference in social function with respect to baseline function46–48. 
 Treatment-related changes in activities of daily living have been mapped 
out in longitudinal studies of AML, MDS, and multiple hematological 
malignancies33,49. Prior to treatment, 37% of a heterogeneous sample33 and 20% 
of MDS/AML49 patients reported impairments in activities of daily living. During 
treatment, 21% of MDS/AML patients reported impairments in activities of daily 
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living 1-month following treatment, though no significant difference was found 
with respect to baseline measurements.  
 Together, these studies indicate that better quality of life is a consequence 
of effective symptom management and contributes to overall societal impact. 
More work is necessary to elucidate symptom changes in patients across each 
hematological malignancy, and replication is necessary to confirm the pattern of 
symptoms reviewed above. Moving forward, however, more rigorous tools are 
needed to evaluate cancer-related symptoms. Specifically, these subjective 
measures are based solely on patient report. Critically, subjective and objective 
impairments are weakly related2–6, suggesting patient reports may not reflect 
clinical standards for impairment. In the following section, objective clinical 
measures of cognitive function are evaluated.  
Cognitive Impairment in Hematological Malignancies 
Overview 
Previous studies noting subjective changes in cognitive function are 
limited by the lack of knowledge regarding the construct validity in self-
assessment tools64. Indeed, breast cancer studies have demonstrated weakly 
significant relationships between subjective cognitive function and objective 
cognitive performance59, as determined by self-assessments and neurocognitive 
examinations, respectively. Neuropsychology testing instruments have been 
developed and validated to measure objective cognitive functions that are linked 
with known neurological disease and injury65. Thus, neuropsychology 
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instruments are critical to understanding the nature and impact of cognitive 
impairment in hematological cancer patients. 
Cross-sectional studies40,43,52,53,66–69 have noted impaired objective 
cognitive performance across heterogeneous patient populations after either 
chemotherapy alone (Ctx+) or hematopoietic stem cell transplant (HSCT) 
following high-grade chemotherapy. Percentages of study samples 
demonstrating impaired cognitive performance ranges between 12%67 and 
75%66, where up to 39% of patients showed impairment 9.5 years following 
treatment53. Due to the nature of cross-sectional study designs, it is difficult to 
determine whether disease- or treatment-related factors contribute to cognitive 
impairment. In contrast, longitudinal studies of patients prior to either Ctx+ or 
HSCT at least have baseline evaluations for comparison. For this reason, cross-
sectional studies are not fully evaluated here. In the following sections, the 
impact of chemotherapy and HSCT are evaluated in turn to assess their 
respective contribution to cognitive impairment in hematological cancer patients.  
Chemotherapy-Related Impairment 
In a sample (n=68) of diffuse large B-cell non-Hodgkin lymphoma (DLBCL) 
patients70, Khan and colleagues examined the effects of CHOP 
(cyclophosphamide, doxorubicin, vincristine, prednisone) (n=34) and R-CHOP 
(rituximab + CHOP) (n=34) on cognitive function using the Mini-Mental State 
Exam (MMSE)71,72. Cognitive function was evaluated prior to starting the first 
(TP0), second (TP1), third (TP2), and fourth (TP3) treatment cycles, where each 
treatment cycle lasted three weeks. Study patients were middle-aged adults 
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(43.6±9.1 years), gender balanced (47.1% females), and were primarily 
diagnosed with stage II (43%) or III (41%) disease, though some stage IV 
patients (10%) were included. Patients in both treatment groups showed baseline 
impairments relative to normative data72 and a significant decline in MMSE 
performance across treatment cycles. R-CHOP patients showed significant 
declines at TP2 and TP3 relative to TP0, whereas CHOP patients showed 
significant declines only at TP3 relative to TP0. Greater declines in MMSE 
performance in the R-CHOP group resulted in a significant difference between 
treatment groups at TP3. Thus, Khan and colleagues noted global cognitive 
impairment in DLBCL patients prior to treatment, and after 2 cycles (or 6 weeks) 
of R-CHOP and 3 cycles (or 9 weeks) of CHOP.  
 In a sample (n=30) of chronic myelogenous leukemia (CML) patients55, 
Scheibel and colleagues examined the cognitive effects of interferon-alpha (IFN-
a; n=13) alone or IFN-a and chemotherapy (low dose cytosine arabinoside or 
hydroxyurea; n=17). Cognitive function was assessed across multiple domains 
with six neuropsychology tests: Digit Symbol Substitution (psychomotor speed), 
CLTR (verbal learning), VSRT (verbal recall), Trails A (processing speed), Trails 
B (executive function), and COWA (verbal fluency). Assessments occurred prior 
to treatment and once during treatment. Study patients were middle-aged adults 
(46.5±9.6 years), mostly males (66.7%), and mid-treatment assessment occurred 
significantly later for the IFN-a and chemotherapy group (43.9±40.0 weeks) 
relative to the IFN-a alone group (22.9±24.0 weeks). Test performance was 
noted as impaired if it declined by at least one standard deviation. In total, 53.3% 
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of patients showed a treatment-related decline on at least one test. Declines 
were noted most commonly in CLTR (20%), COWA (13.3%), and Trails B 
(26.7%). Depression symptoms increased in 33.3% of all patients, though no 
relationship was observed between changes in depressive symptoms and 
cognitive performance. Patients receiving IFN-a combination therapy showed 
greater declines in CLTR, COWA, and Trails B performance. Thus, Scheibel and 
colleagues demonstrated treatment-related impairments in verbal learning, verbal 
fluency, and executive function in CML patients following multiple treatment 
cycles. 
 In a sample (n=54) of acute myelogenous leukemia (AML; n=19) and 
myelodysplastic syndrome (MDS; n=35) patients49, Meyers and colleagues 
examined cognitive effects of therapy with lipodaunocin and either cytoxan or 
topotecan, and some patients received an additional dose of thalidomide. 
Cognitive function was assessed seven neuropsychology tests: Digit Span 
(attention), Digit Symbol Substitution (psychomotor speed), HVLT (verbal 
memory), COWA (verbal fluency), Trails A (processing speed), Trails B 
(executive function), and Grooved Pegboard (motor dexterity). Assessment 
occurred prior to treatment (n=54) and one-month after initiating treatment in a 
subset of patients (n=26). Study patients were an average of 60.2 years old (21-
84 years) and gender balanced (44% female). Test scores falling 1.5 standard 
deviations below normative data were noted as impaired. Prior to treatment, 
impairments were most commonly noted in HVLT (44%), Trails B (29%), Trails A 
(28%), and COWA (17%). Following one month of treatment, impairments were 
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most commonly noted in HVLT (58%), Trails B (46%), Trails A (38%), and 
COWA (25%). Although more patients showed treatment-related impairments in 
these tests, the smaller sample at follow-up assessment reduced the power to 
detect these differences. Thus, Meyers and colleagues reported disease- and 
treatment-related impairment in AML and MDS patients in processing speed, 
executive function, verbal fluency, and verbal learning. 
 These studies, which represent the most rigorous evaluation of 
chemotherapy-related cognitive impairment in hematological cancer patients, are 
not without significant limitations. All three studies failed to include a non-
treatment comparison group to rule out disease-related, in contrast to treatment-
related, declines in cognitive function. According to current literature, impaired 
baseline cognitive function likely arose from putative disease-related systemic 
changes50,73. Furthermore, Khan and colleagues70 measured cognitive function 
using the MMSE, a global cognitive screening tool designed to detect severe 
cognitive impairment, whereas cognitive changes reported in cancer patients are 
more consistent with mild cognitive impairment. Critically, the MMSE lacks 
sensitivity to detect mild cognitive impairment within specific cognitive 
domains74,75. Finally, Meyers and colleagues49 studied a smaller subset of the 
initial sample during follow-up assessment, restricting the statistical power to 
detect reliable chemotherapy-related changes in cognitive function. Thus, more 
rigorous study designs and comprehensive neuropsychology batteries are 
required to evaluate evidence for and mechanisms of chemotherapy-related 
cognitive impairment in hematological cancer patients. 
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Transplant-Related Impairment 
 In addition to standard chemotherapy, the toxicity of high-grade 
chemotherapy and HSCT poses an additional risk to cognitive function. 
Compared to the volume of chemotherapy-related cognitive impairment studies 
reviewed above, substantially more studies have investigated transplant-related 
cognitive impairment. In the following section, each study is grouped according to 
transplant type.  
 Allogeneic Transplant. Scherwath and colleagues76 evaluated a study 
sample (n=102; 50.4±12.6 years; 67% males) comprised primarily of AML 
patients (41%) prior to (T0), 100±20 days after (T1), and 12±1 months (T2) after 
allogeneic HSCT. Cognitive function was examined in the domains of verbal 
working memory, visual working memory, verbal memory, reaction time, and fine 
motor function. No comparison groups were included, though performance was 
compared to normative data65 and reliable change scores77. Prior to undergoing 
HSCT (T0), 47% of patients showed impairment in at least one domain, which 
may be explained by previous treatment with chemotherapy or autologous SCT 
in 80% of patients. Following HSCT (T2), 41% of patients showed impairment in 
at least one domain, and 72.6% of patients showed declines from T0 to T2. Older 
adults, lower education, and lower premorbid intelligence were associated with 
probability of cognitive impairment.  
 Schulz-Kinder and colleagues78 examined a study sample (n=21; 
41.7±12.4 years; 67.7% males) comprised primarily of AML patients (48%) prior 
to (T0) and 100±20 days after (T1) allogeneic SCT. Prior to SCT, 68.3% of 
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patients received medium to strong induction chemotherapy. Cognitive function 
was examined in the domains of processing speed (Trails A), working memory 
(Digit Span, Visual Memory Span), verbal memory (VLMT), and executive 
function (Trails B, Go/NoGo). No comparison groups were included, though 
impairment was noted for test scores greater than 1.4 standard deviations below 
normative data 65. Prior to (T0) and following (T1) HSCT, up to 26.3% and 42.1% 
of patients, respectively, showed cognitive impairment. There were no significant 
changes in cognitive function between T0 and T1 assessments.  
 Sostak and colleagues79 examined a study sample (n=71; 37±9 years; 
61% males) comprised primarily of AML (31%) and CML (45%) patients prior to 
(T0; 2±4 months) and 14 months after (T1) allogeneic HSCT. All CML and AML 
patients (and 96% of enrolled patients) had undergone induction chemotherapy 
prior to T0 assessment. In addition to neurological examination, cognitive 
function was examined in the domains of processing speed (Trails A, Digit 
Symbol Modalities) and executive function (Verbal Fluency Test, Stroop). No 
comparison groups were included, though test scores were considered impaired 
if they one standard deviation below the mean of normative data generated by 
the lab. Prior to HSCT, 62% and 58% of patients showed signs of abnormal 
neurological and neuropsychology status, respectively. Baseline neurological 
complications were primarily observed as tremors (38%) and impaired saccadic 
smooth pursuit (19%), and baseline neuropsychological impairments were 
observed primarily in the structured interview (36%), verbal fluency (24%), and 
Stroop interference scores (15%). At T1, 57% and 51% of patients showed 
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neurological and neuropsychological complications, respectively. Compared to 
T0 status, 47% and 31% of patients showed new neurological and 
neuropsychological complications, respectively. Negative outcomes were 
associated with pre-SCT chemotherapy, transplant from an unrelated donor, and 
graft-versus-host disease (GvHD). Interestingly, 53% of patients with impaired 
neuropsychological performance at T0 showed improvement at T1, and gender 
(female) and disease duration (<20 months) were associated with positive 
outcomes.  
 Chang and colleagues80 examined a study sample (n=106) of CML (86%; 
45.2±11.9 years; 52% males) and MDS patients (14%; 64.8±9.3 years; 73% 
males). Patients underwent allogeneic HSCT (44%) or imatinib mesylate. 
Transplant patients completed assessments prior to (T0; 67±106 days), 12 
months after (T1) and 18 months after (T2) allogeneic HSCT; other treatment 
patients completed assessments at the same intervals. Cognitive function was 
examined in the domains of processing speed (Trails A), executive function 
(Trails B, VFT), verbal learning and memory (Selective Reminding Task), and 
motor function (Grooved Pegboard). Cognitive performance was normalized to z-
scores based on age, sex, and education per normative data81–84. Test 
performance was compared across transplant and non-transplant groups. 
Patients improved across testing intervals in measures of verbal learning and 
memory; no measures revealed a decline in cognitive performance. CML patients 
performed better than MDS patients in measures of motor control, processing 
speed, and executive function. Transplant patients performed worse than non-
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transplant patients in measures of motor control. These authors failed to report 
proportion of patients performing lower than normative data. Exclusion of a 
comparison group precluded evaluating changes in test performance relative to 
healthy controls. Thus, these data should be evaluated with caution, as 
improvements in test performance may reflect practice-related effects.  
 Meadows and colleagues85 examined a study sample (n=77; 48.6±13.7 
years; 52% males) of CML (89%) and MDS (11%) patients prior to (T0), 12 
months after (T1), and 18 months after (T2) allogeneic HSCT. Cognitive function 
was examined in the domains of processing speed (Trails A; Digit Symbol 
Coding), attention (Digit Span), executive function (Trails B, VFT, Stroop), verbal 
memory (Selective Reminding Task), and motor control (Grooved Pegboard). No 
comparison groups were included, though impairment was noted for test scores 
greater than 1.4 standard deviations below normative data 65. At T0, 81% of 
patients showed cognitive impairment on at least one test, with impairments 
primarily noted in memory (34%), motor control (32%), and executive function 
(16%). At T2, 36% of patients showed cognitive impairment on at least one test, 
and patients were significantly impaired in the domains of processing speed, 
motor control, and verbal memory. Younger patients, CML patients, and patients 
with higher baseline language performance were more likely to improve over 
time. 
 Syrjala and colleagues86 examined a study sample (n=142; 41.5±9.3 
years; 49% males) comprised of patients primarily diagnosed with CML (50%), 
acute leukemia (21%), and MDS (13%). Patients were assessed prior to (T0), 2.6 
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months after (T1), and 12 months after (T2) allogeneic HSCT. Before study 
enrollment, all patients received systemic chemotherapy, with 48% receiving 
hydroxyurea and 12% receiving interferon, and 63% of patients received total 
body irradiation. Cognitive function was examined in the domains of processing 
speed (Digit Symbol Coding), executive function (Trails B, COWA, WCST), 
verbal memory (HVLT), and motor control (Grooved Pegboard). No comparison 
groups were included, though impairment was noted for test scores greater than 
1 standard deviation below normative data. At T0, 71% of patients showed 
cognitive impairment, with deficits primarily noted in COWA (32%), HVLT (32%), 
Trails B (22%), and Digit Symbol Coding (21%). At T1, 94% of patients showed 
cognitive impairment, with deficits primarily noted in COWA (56%), HVLT (44%), 
Digit Symbol Coding (35%), and Trails B (27%). At T2, 74% of patients showed 
cognitive impairment, with deficits primarily noted in COWA (33%), HVLT (33%), 
Digit Symbol Coding (21%), and Trails B (15%). HSCT patients showed chronic 
impairments in COWA and HVLT performance across all study visits, and 
showed acute impairments at T1 in Trails B and Digit Symbol Coding 
performance. Patients not receiving chemotherapy or receiving hydroxyurea only 
were less likely to be impaired at T0. Of all patients not showing impairment at 
T0, 54% showed new impairment at T2.  
 Allogeneic/ Autologous Transplant. Harder and colleagues87 examined a 
study sample (n=25; median age of 47; 64% males) comprised of patients 
primarily diagnosed with MM (28%) and NHL (16%). Patients were assed prior to 
(T0), 6 months after (T1), and 12 months after (T2) either allogeneic (76%) or 
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autologous (24%) HSCT. Prior to HSCT, 40% of patients were classified as high 
risk disease and 80% of patients received at least one course of chemotherapy. 
Cognitive function was examined in the domains of processing speed (Trails A), 
attention (Digit Span), executive function (Stroop, Trails B, VFT), visual memory 
(CFT), and verbal memory (CVLT). No comparison groups were included, though 
impairment was noted for test scores greater than 2 standard deviation below 
normative data. At T0, impairments were primarily observed in the domains of 
processing speed, attention, and executive function. At T2, no evidence of 
impairment was observed, but memory performance improved relative to T0.  
 Meyers and colleagues88 examined a study sample (n=61; 37.5 years; 
56% males) comprised of patients primarily diagnosed with CML (43%), NHL 
(20%), and AML (10%). Patients were assed prior to (T0), 0.4 months after (T1), 
discharge (T2), and 8 months after (T3) either allogeneic (69%) or autologous 
(31%) HSCT. Prior to HSCT, 35% of patients received chemotherapy treatment 
with interferon-alpha. Cognitive function was assessed with the Dementia Rating 
Scale (DRS)89, a brief cognitive screening tool developed to broadly assess 
cognitive functions. No comparisons groups were included, though impairment 
was noted for test scores greater than 2 standard deviation below normative 
data. Overall test performance was impaired in 20%, 13%, 23%, and 10% of 
patients at T0, T1, T2, and T3, respectively. DRS performance at T0 predicted 
changes in anxiety and depression at T2, such that higher DRS performance was 
associated with lower anxiety and depression at follow-up. No association was 
reported between cognitive function and HSCT type.  
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 Harder and colleagues90 examined a study sample (n=101; 42.0±12.1 
years; 61% males) comprised of patients primarily diagnosed with NHL (29%), 
acute leukemia (27%), chronic leukemia (17%), and MM (17%). Patients were 
assessed prior to (T0), 8 months after (T1), and 20 months after (T2) either 
allogeneic (66%) or autologous (34%) HSCT. Prior to HSCT, 98% of patients 
were given conditioning treatment primarily with high-dose cyclophosphamide 
(74%). HSCT patients were compared to a non-transplant comparison group 
(n=82; 39.2±13.1; 45%) comprised primarily of NHL (35%) and HD (60%) 
patients, most of which (90%) received chemotherapy. Cognitive function was 
examined in the domains of processing speed (Trails A, Digit Symbol 
Substitution), attention (Digit Span), executive function (VFT, Stroop, Trails B), 
visuospatial reconstruction (Blocks), visual memory (CFT, BVRT), and verbal 
memory (CVLT). Performance in both groups was compared to normative data, 
and scores greater than 2 standard deviations below means were noted as 
impaired. Prior to transplant, impaired cognitive function was observed across 
both groups in the domains of processing speed, visual memory, and verbal 
memory. Between-group differences failed to reach significance at baseline. 
Although no significant declines were observed across testing intervals, HSCT 
patients performed worse than comparison groups in the domains of processing 
speed, attention, and executive function.  
 Friedman and colleagues91 examined a study sample (n=117; 45.4±11.9 
years; 59% males) comprised of patients primarily diagnosed with NHL (30%), 
MM (19%), and CML (15%). Patients were assessed prior to (T0), 1.5 months 
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after (T1), and 7 months after (T2) either allogeneic (49%) or autologous (51%) 
HSCT. Cognitive function was examined in the domains of processing speed 
(Trails A, Digit Symbol Substitution), attention (Digit Span), executive function 
(Trails B, COWA), and verbal learning (HVLT). No comparison groups were 
included, though test performance greater than 2 standard deviations below 
normative data were noted as impaired. Prior to transplant, 39% of patients 
showed cognitive impairment in Trails A (23%), Trails B (25%), COWA (13%), 
and HVLT (27%). Reliable declines in performance were found in 47% of patients 
at T1, and 33% of those patients showed further decline at T2. Declines in 
cognitive function was not predicted by transplant type, age, education, or 
psychosocial function.  
 Jacobs and colleagues92 examined a study sample (n=388; 50.1±12.4 
years; 54% males) comprised of patients primarily diagnosed with MM (63%), 
NHL (10%), and AML (7%). Patients were assessed prior to (T0), 6 months after 
(T1), and 12 months after (T2) either allogeneic (21%) or autologous (79%) 
HSCT. Cognitive function was examined in the domains of processing speed 
(Trails A, Digit Symbol Substitution), attention (CPT), executive function (Trails B; 
COWA; Stroop), verbal memory (CVLT), and motor control (Grooved Pegboard). 
No comparison groups were included, though test performance greater than 1 
standard deviation below normative data were noted as impaired. Prior to 
transplant, 16% of patients showed global cognitive impairment, with 
impairments noted specifically in the domains of attention (23%), verbal memory 
(19%), and motor control (89%). Across cognitive domains, excluding attention, 
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performance improved with time. As with other studies failing to include a 
comparison group, improvements in performance should not be interpreted as 
transplant-related improvement in cognitive function.  
 Autologous Transplant. Jones and colleagues93 examined a study sample 
(n=53; 57.8±8.2 years; 62.3%) comprised of MM patients scheduled to undergo 
autologous SCT. Patients were assessed prior to (T0), 1 month after (T1), and 3 
months after (T2) transplant. All patients underwent at least one induction 
chemotherapy cycle, and 77.1% of patients underwent at least three induction 
chemotherapy cycles. Most patients (86.8%) received bortezomib-based 
induction treatment. Cognitive function was examined in the domains of 
processing speed (Trails A, Digit Symbol Substitution), attention (Digit Span), 
executive function (Trails B, COWA), verbal memory (HVLT), and motor control 
(Grooved Pegboard). No comparison groups were included, though test 
performance greater than 2 standard deviations below normative data were 
noted as impaired. Prior to transplant, 47.2% of patients showed impaired 
cognitive function on at least one test, with impairments noted primarily in 
performance on Trails A (11.3%), Trails B (20.8%), COWA (20.8%), and HVLT 
(28.3%). At T1, 48.8% of patients showed reliable decline in cognitive 
performance relative to T0, with impairments noted primarily in the domains of 
verbal memory (29.3%) and motor control (15%). At T2, 48% of patients showed 
reliable decline in cognitive performance relative to T1. Of all patients showing 
decline at T1, 50% showed further decline at T2; of all patients not showing 
decline at T1, 46% showed new decline at T2. Factors that predicted declines in 
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cognitive function were pre-transplant impairment, number of induction treatment 
cycles, education, and subjective complaints of “difficulty remembering” and 
“difficulty paying attention.”  
Comparing Patterns of Objective and Subjective Cognitive Impairment 
 As noted above, there is considerable debate regarding the predictive 
validity of self-assessments to screen for cognitive impairment2–6. Similar 
discrepancies are present in the current literature on subjective and objective 
measures of cognitive function in hematological cancer patients. Evidence for 
chemotherapy-related cognitive impairment based on subjective measures varies 
based on study design. Cross-sectional studies have consistently demonstrated 
self-perceived cognitive impairment in post-treatment patients39–45,53. In contrast, 
longitudinal studies have consistently failed to demonstrate self-perceived 
cognitive impairment during47,48 and following46–48 treatment with respect to 
baseline reports. Consistent evidence for chemotherapy-related cognitive 
impairment has been demonstrated by studies implementing objective measures. 
Multiple cross-sectional studies have demonstrated cognitive impairment in post-
treatment patients40,43,52,53,66–69. Furthermore, longitudinal studies have 
demonstrated cognitive impairment prior to treatment49,70,76,78,79,85–87,91–93 and 
further decline in cognitive function following treatment49,55,70,76,79,86,91,93, 
demonstrating direct evidence for treatment-related cognitive impairment. Some 
studies have failed to show treatment-related declines in cognitive 
function80,87,9290. Critically, however, these studies were constrained by lack of a 
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comparison group to rule out well-documented practice effects in neurocognitive 
exams. 
 Studies directly comparing subjective and objective outcomes best 
demonstrate low predictive validity of self-perceived cognitive function. Of 
importance, these studies40,43,53 exclusively examined lymphoma patients. 
Wouters and colleagues40 demonstrated lower self-reported cognitive function in 
patients treated with chemotherapy. Although no significant impairment in raw 
objective performance was found, 16% of patients were impaired based on 
normative data obtained from healthy comparisons. Subjective cognitive 
measures were similar between impaired (16%) and unimpaired (84%) patients, 
failing to show a relationship between objective and subjective cognitive function. 
Krolak and colleagues43 demonstrated a higher frequency of impairment on both 
objective and subjective cognitive measures. Although these two measures were 
significantly correlated, the weak correlation coefficient (r=.29) indicated 
subjective cognitive function accounted for only 8% of the variance in objective 
cognitive function. Furthermore, pain was associated with objective cognitive 
function whereas fatigue and anxiety were associated with subjective cognitive 
function, suggesting separable psychosocial factors contribute to objective and 
subjective function. Ahles and colleagues53 demonstrated worse objective and 
subjective cognitive function in patients treated with chemotherapy compared to 
patients treated with local therapy. In contrast to Krolak and colleagues, 
correlations between objective and subjective cognitive function failed to reach 
significance.  
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 These studies demonstrate the poor predictive validity of cognitive self-
assessments to screen for clinically-relevant cognitive impairment. Critically, 
however, these studies were cross-sectional by design, precluding the ability to 
evaluate the relationship between treatment-related changes in subjective and 
objective measures. Thus, longitudinal studies comparing objective and 
subjective measures are critical to evaluating whether self-assessments are 
sensitive to acute changes in cognitive function. 
Neural Mechanisms of Cognitive Impairment 
 Cognitive functions studied in cancer populations emerges from dynamic 
patterns of neural activity in function-specific cortical regions94,95. Neural activity 
can be measured in both the spatial and temporal domain. Magnetic resonance 
imaging (MRI) and positron emission tomography (PET) are two neuroimaging 
modalities that provide high spatial resolution measures of neural activity. MRI 
and PET measure brain structure and function with millimeter-level resolution, 
isolating putative changes to specific cortical regions. In contrast, 
electroencephalography (EEG) and magnetoencephalography (MEG) are two 
neuroimaging modalities that provide high temporal resolution measures of 
neural activity. EEG and MEG measure brain function with millisecond-level 
resolution, isolating changes in neural activity associated with specific cognitive 
functions. To develop more rigorous tools to evaluate cognitive function in cancer 
patients, chemotherapy-related changes in cognitive function must be 
understood through precise mechanisms affecting structural and functional 
changes to the brain. In the following section, studies that have utilized 
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neuroimaging modalities are reviewed to place cognitive findings in biological 
context.  
  Chemotherapy-Related Changes. Two cross-sectional studies52,96 of 
primarily NHL survivors have evaluated PET differences in Ctx+ patients 
approximately 7-months post-treatment compared to Ctx- patients. Both studies 
found chemotherapy-related changes in the dorsal attention network (DAN) and 
central executive network (CEN), a constellation of cortical regions critical to 
spatial attention, working memory, and executive functions97–99. Baudino and 
colleagues52 examined patients prior to (n=18) and up to 8-months after (n=32) 
treatment. Neurocognitive measures of executive function (Trails B) showed 
greater impairment in Ctx+. PET activity was reduced in Ctx+ patients compared 
to HC participants; furthermore, PET activity correlated negatively with number of 
chemotherapy cycles and positively with time since chemotherapy, suggesting 
Ctx+ patients experience acute changes in brain metabolism during treatment 
and recovery of normal brain metabolism following treatment. Importantly, PET 
activity correlated with executive function, though this correlation failed to 
withstand correction for multiple comparisons.  
 D’Agata and colleagues96 compared NHL survivors (n=14) approximately 
7-months post-treatment to NHL survivors not treated with chemotherapy (n=14). 
Multivariate pattern classification methods revealed patterns of neural activity 
within DAN and CEN correctly discriminated between Ctx+ and Ctx- patients with 
80% accuracy. Interestingly, average DAN activity was indistinguishable between 
patient groups, suggesting more information regarding chemotherapy-related 
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cognitive impairment could be extracted from patterns of activity rather than 
overall mean activity levels. These pattern differences may be associated with 
well-documented age-related shifts of neural activity100,101, in which more frontal 
activity may be recruited as a compensatory mechanism to overcome 
impairments in parietal cortex.  
 In one EEG study41, NHL survivors were compared to healthy controls 
approximately 3-months post-chemotherapy. NHL survivors were divided into two 
groups based on treatment (R-CHOP, BR). Individual differences in alpha peak 
frequency (iAPF), a dominant neural rhythm associated with sleepiness102,103 and 
cognitive function104–106, were assessed. Higher iAPF are associated with better 
cognitive function, such as attention and memory107, and are lower in traumatic 
brain injury patients108. Zimmer and colleagues41 found no significant difference 
in iAPF between Ctx+ and healthy comparisons. Although BR patients trended 
toward lower iAPF values, suggesting greater cortical impairment compared to R-
CHOP patients, NHL patients demonstrated higher iAPF values than HC, 
suggesting greater cortical impairment in HC. These results contradict the 
conclusion made by these authors, who suggested cognitive and neural function 
was more impaired in NHL patients, and that BR patients were more susceptible 
to impairment. Potential explanations for these conflicting findings include a small 
sample size and overall poor EEG measure of cognitive function.  
Transplant-Related Changes. Three cross-sectional MRI studies69,109,110 
have examined primarily leukemia patients post-transplant to evaluate the 
presence of central nervous system (CNS) abnormalities. Mohrmann and 
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colleagues109 studied patients 3.6 months post-transplant. Of all patients studied, 
72% showed CNS abnormalities, which were most commonly classified as 
cerebrovascular lesions; approximately half of all lesions developed prior to 
transplant. Graus and colleagues110 studied patients 12 months post-transplant. 
Of all patients studied, 11% showed CNS abnormalities, which were most 
commonly classified as cerebral hemorrhage and metabolic encephalopathy. 
Patients undergoing allogeneic HSCT, when compared to patients undergoing 
autologous HSCT, were more likely to develop CNS abnormalities (8% vs 0.6%) 
and neurologic complications (13% vs 11%). Padovan and colleagues69 studied 
patients 34 months post-transplant. Of all patients studied, 60% showed CNS 
abnormalities, which were most commonly noted in white matter tracts of frontal 
(76%), parietal (52%), and temporal (34%) cortices. Furthermore, 64% of 
patients showed neurological impairment and 37% of patients showed cognitive 
impairment. Importantly, medical chart reviews indicated no neurological 
symptoms prior to transplant, suggesting abnormalities were transplant-related. 
Consistent with findings from Gaus and colleagues110, Padovan and colleagues 
demonstrated greater risk for allogeneic than autologous HSCT patients for CNS 
abnormalities (RR=3.3), neurological impairments (RR=5.0), and cognitive 
impairment (RR=3.3). 
One longitudinal study79 examined leukemia patients prior to (T1) and 14-
months post-transplant (T2). CNS abnormalities were noted in 56% of studied 
patients, with 2% of patients showing new abnormalities at T2; abnormalities 
were most commonly noted in white matter tracts of frontal (80%), parietal (28%), 
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and temporal (28%) cortex. Neurological impairments were found in 65% of 
patients, with 47% of patients developing new complications between T1 and T2. 
Transplant-related cognitive impairment was identified in 57% of patients, with 
verbal fluency and Stroop performance most frequently impaired. Patients 
receiving chemotherapy or radiation prior to transplant were at a higher risk for 
neurological complications.  
Animal Models 
 Animal models provide a robust experimental design platform for 
investigating the neural mechanisms of chemotherapy-related cognitive 
impairment. Using animal models (e.g. mice, rats), investigators administer 
chemotherapy to systematically examine drug-induced neurotoxicity. These 
studies have demonstrated chemotherapy-related changes to neuronal survival 
and morphology111–129, neuronal function122,130,131, neurotransmitter 
function114,130,132–141, proinflammatory cytokine levels139–141, and cognitive 
function111,114,116–118,120,142–146. Each class of chemotherapy agents have been 
associated with specific patterns of neurotoxicity, which are briefly reviewed 
below. 
 Alkylating agents cause DNA damage, resulting in reduction of cell 
populations, particularly those that rapidly proliferate (i.e. malignant cells)147,148. 
Alkylating agents – cisplatin, cyclophosphamide, and busulfan – are commonly 
used to treat hematological malignancy. Impaired spatial cognition has been 
shown in studies of both cisplatin111 and cyclophosphamide114,143,144. Cisplatin 
has been shown to induce morphological changes such as a reduction in 
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dendritic branching111, dendritic spine density111,112, mitochondrial degradation111, 
and neuronal apoptosis in hippocampus112. Cisplatin has also been associated 
with changes in NMDA132,133 (N-methyl-D-aspartate) and AMPA133 (a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid) receptor expression, both of which 
are glutamate receptors. Cyclophosphamide has been shown to decrease 
neuronal growth113,114,125, induce neuronal apoptosis113, increase levels of neural 
activity in the hypothalamus149, and reduce bone-derived neurotrophic factor 
(BDNF) levels114, a nerve growth factor that promotes neuronal survival. Busulfan 
has been shown to induce thinning of the cerebral cortex119, 
microencephalopathy119, and inhibition of proliferation in neural progenitor 
cells115.  
 Antimetabolites block cellular metabolic pathways, resulting in cell cycle 
arrest and apoptosis150. Antimetabolites – cladribine, hydroxyurea, methotrexate 
– are commonly used to treat hematological malignancy. Cladribine and 
methotrexate have been shown to inhibit cell proliferation116–118,126, including 
microglia126 and hippocampal cells116–118. Hydroxyurea and methotrexate have 
been shown to reduce white matter volume, including regions of the 
cerebellum121 and corpus collosum117, and increase circulating levels of 
proinflammatory cytokines139,140. Methotrexate has been associated with 
apoptosis of hippocampal cells116,128, changes in synaptic plasticity-related neural 
activity in hippocampus130, and impaired spatial memory116–118,142. Furthermore, 
methotrexate has been shown to induce changes in NMDA and BDNF 
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expression130, similar to what has been shown with cisplatin132,133 and 
cyclophosphamide114, respectively.  
 Plant alkaloids disrupt microtubule function and DNA folding, resulting in 
cell cycle arrest151,152. Plant alkaloids – vincristine, etoposide, and doxorubicin – 
are commonly used to treat hematological malignancy. Vincristine has been 
associated with reductions in axonal excitability122 followed by axonal 
degeneration and demyelination122,123, damage to hippocampal structures120, and 
impairments in learning and memory120,145,146. Etoposide has been associated 
with decreased proliferation and apoptosis of neural progenitor cells129. 
Doxorubicin has been associated with reduced glutamate update in frontal cortex 
and dentate gyrus135, and reduction in dopamine concentrations in frontal cortex, 
hippocampus, and striatum136.  
 Newer classes of chemotherapy agents, including proteasome inhibitors153 
and immunomodulatory agents154, are being developed to treat multiple 
myeloma. Bortezomib, a proteasome inhibitor, has been associated with 
peripheral neuropathy124,131,155, affecting primarily the dorsal root ganglion155 and 
sciatic nerve124, and increasing neurophysiological activity in peripheral nerve 
fibers in response to innocuous spikes131. Furthermore, bortezomib has been 
associated with a decrease in plasma BDNF134, resulting in a suppression of 
neuronal repair, and an increase in tumor necrosis factor-alpha (TNF-a) levels in 
DRG131,141. Thalidomide, an immunomodulatory agent, has been associated with 
decreases in inflammatory markers156,157 and prevention of memory 
impairment157, reduced upregulation of NMDA receptor subunits in hippocampus 
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(but not prefrontal cortex) 156, decrease in dopamine metabolism and number of 
dopaminergic neurons137, and decrease in serotonergic release into synaptic 
cleft138.   
Research Proposal 
In both animals and humans, multiple studies have demonstrated 
detrimental effects of hematological malignancy and chemotherapy agents on 
neurotransmitter systems, cortical structure and function, cognition, and 
psychosocial status. Animal studies have demonstrated chemotherapy-related 
degradation in cortical structure as a result of changes in neural progenitor cell 
proliferation115–118,126,129, neuronal degradation111–114,122,123,125 and 
apoptosis112,113,116,128,129, and BDNF levels critical to neuronal repair 
mechanisms114,130,134. Changes in cortical structure are preceded by changes in 
neurophysiological activity122,130,131,149, which is mediated by changes in 
neurotransmitter metabolism and receptor expression, including 
glutamate130,132,133,135, dopamine136,137, and serotonin138. Changes in cortical 
structure and function are directly associated with impairments in spatial 
cognition111,114,116–118,120,142–146.  
Human studies have demonstrated chemotherapy-related degradation of 
cortical structures in frontal, parietal, and temporal cortex69,79, which have 
primarily resulted from cerebrovascular lesions109,110 and metabolic 
encephalopathy110. Changes in functional activity have been shown in dorsal 
attention and executive control cortical networks52,96, which encompass a 
constellation of cortical regions that largely overlap with regions of changes. 
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Numerous studies have demonstrated cognitive impairment prior to49,70,76,78,79,85–
87,91–93 and after40,43,49,52,53,55,66–70,76,79,86,91,93 treatment, with some longitudinal 
studies demonstrating treatment-associated declines in cognitive function 
following treatment49,55,70,76,79,86,91,93. Impairments were noted primarily in the 
cognitive domains of processing speed49,85,87,90,91,93, executive function49,55,85–
87,91–93, and memory85,90,9249,86,91,93. Although some studies failed to observe 
treatment-related changes in cognitive function80,87,9290, these studies were also 
constrained by poor study design, such as a lack of comparison groups to rule 
out practice effects on neurocognitive exams.  
Objective cognitive measures, which revealed chemotherapy-related 
impairments, fail to predict self-reported cognitive function40,43,53. In contrast, 
subjective cognitive impairment may be a better indication of psychosocial 
distress158,159, suggesting non-overlapping mechanisms between cognitive 
function and awareness of cognitive function160–162. Indeed, quality of life studies 
have demonstrated chemotherapy-related changes in physical function33,38–49, 
emotional function38–41,43,44,55, cognitive function39–45,53, and role function33,44,46–
49,60–63, including employment, social activities, and activities of daily living (e.g. 
driving). Importantly, overall survival was predicted by baseline cognitive 
function33 and maintaining physical activity34–37.  
Currently, there exists no translational research program designed to 
integrate the temporal, spatial, and biological scales necessary to 
comprehensively study the complex system of mechanisms underlying 
chemotherapy-related cognitive impairment. The goal of the current dissertation 
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research was to begin this program by developing an interdisciplinary 
translational neuroscience toolbox.  
Theoretical Framework. 
Identifying the biological mechanisms through which cancer 
pathophysiology and treatment toxicity induces cognitive impairment is critical to 
developing prevention and control strategies. Several reviews have attempted to 
develop a theoretical framework for the emergence of chemotherapy-related 
cognitive impairment based on animal and human breast cancer studies163–169. 
Figure 1 provides a general overview of the proposed biological mechanisms. 
Acknowledging limitations of chemotherapy agents crossing the blood brain 
barrier163–165,167, these reviews propose peripheral activation of proinflammatory 
pathways circumvents the blood brain barrier by inducing neuroinflammation 
through microglia activation163–168.  Subsequently, these reviews generally 
converge on the same inflammation-mediated mechanisms of downstream 
cognitive impairment: (1) structural degradation163–165,167,168; (2) oxidative stress 
on neuronal metabolism163–165,167,168; (3) impaired neurogenesis and neuronal 
repair163,167,168; and (4) neurotransmitter dysregulation164–167.  
 The current research aimed to apply this theoretical framework of 
chemotherapy-related cognitive impairment to similar patterns of cognitive 
impairment in hematological malignancy patients. Extending this framework, the 
current research also aimed to identify central cognitive functions most 
vulnerable to the chemotherapy-induced inflammatory pathways. Impairments to 
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these central cognitive functions may predict downstream impairment of 
additional cognitive functions.  
Attention is a capacity-limited cognitive system that mediates information 
processing, selecting relevant information, and ignoring irrelevant information. 
For example, ignored information would be unavailable for memory storage. 
Therefore, efficient control of these attention functions would have direct 
consequences on downstream cognitive functions that operate only on 
information selected and stored online. Indeed, converging evidence in breast 
cancer studies support the hypothesis that chemotherapy-related cognitive 
impairment arises from direct insults to neural networks supporting attention169.  
Behavioral33,49,70 and neuroimaging52,96 studies of hematological 
malignancy patients collectively suggest cognitive impairment may arise from 
changes in the dorsal attention and executive control networks96. It remains 
unclear, however, if these brain networks are altered in pre-treatment patients 
because previous studies lacked prospective evaluation and non-treatment 
comparison groups. In contrast, chemotherapy-related cognitive impairment has 
been more thoroughly studied in breast cancer patients170–176. In neuroimaging 
studies of these patients, an emerging hypothesis suggests cognitive impairment 
may be attributable to dysfunction in the executive function network (EFN)175,177. 
EFN promotes long-range communication between frontal and parietal cortical 
regions178,179, and is associated with working memory and attentional control 
processes180–182. Accumulating evidence has shown chemotherapy-related 
changes in: (1) cognitive measures of processing speed, attention, and working 
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memory170–173,175,176,183–185; and (2) EFN structural morphology and functional 
activity175,177,184–189. In one study, pre-treatment breast cancer patients showed a 
relative decrease in functional MRI activity within superior parietal lobule (SPL) 
and a relative increase in functional activity in the precuneus, medial frontal gyrus 
(MFG), and inferior parietal lobule (IPL) during a working memory task187. 
Patients showed treatment-related reductions in SPL, MFG, precuneus, and 
inferior frontal gyrus (IFG) one-month and twelve-months post-treatment. 
Importantly, these cortical regions are associated with attentional control 
processes181,190. Thus, converging evidence between studies of breast and 
hematological malignancy patients suggests impairments in attentional control 
networks may underlie a common mechanism for chemotherapy-related 
cognitive impairment73,191.  
Attentional Control. 
Mechanisms of attentional control modulate the processing of incoming 
sensory information by selecting goal-relevant information and gating goal-
irrelevant information192–195. Selection mechanisms include shifts of spatial or 
feature-based attention, stimulus processing and encoding, storage in working 
memory, and storage in or retrieval from long-term memory. Gating mechanisms 
include stimulus suppression, disengaging from stimulus processing, and control 
over inhibitory processes. Goal-relevant information is available to the observer 
either externally or internally, corresponding to information in space or mind, 
respectively193,194. Furthermore, impaired attention mechanisms are associated 
with detrimental real-world consequences, including declines in automobile 
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driving performance196–198 and increases in crash risk198–200. Collectively, these 
cognitive mechanisms are largely responsible for controlling active mental 
representations, and govern the degree to which observers are engaged in their 
environment and goals. 
Two primary cortical pathways govern attentional control mechanisms201. 
Dorsal attention network (DAN) is comprised of the intraparietal sulcus (IPS), 
superior parietal lobule (SPL), and frontal eye fields (FEF)178; these regions are 
retinotopically organized and coordinate the locus of spatial attention through 
top-down attentional control. Ventral attention network (VAN) is comprised of 
inferior parietal lobule (IPL), superior temporal gyrus (STG), inferior frontal gyrus 
(IFG), and medial frontal gyrus (MFG)178; these regions are involved in bottom-up 
stimulus processing and filtering irrelevant information. Reciprocal cortical 
interactions between dorsal and ventral attention networks modulate feature-
selective neural activity in sensory cortex to control stimulus selection178,179,202–
205. Populations at risk for functional impairments within attentional control 
networks, including older adults101, show declines in both selection and inhibitory 
control mechanisms206–210.  
Attentional control functions have been associated with dopaminergic211–
214 and serotonergic211,215–219 neurotransmitter systems. In both systems, 
attentional control is associated with neurotransmitter concentration211,213,215,216, 
receptor function214,217, and regulatory genes212,218,219. Furthermore, some 
studies have demonstrated a link between attentional control mechanisms and 
inflammatory immune responses220–223. For example, systemic inflammation is 
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associated with impaired executive function performance220,223, reduced visually-
evoked activity in primary visual cortex221, and dysfunctional neural activity in 
frontal cortex222. Together, these studies indicate that attentional control 
mechanisms are governed by cortical and systemic systems that are particularly 
susceptible to tumor microenvironments and chemotherapy agents, as 
demonstrated in previous studies of human cancer patients and animal models.  
Specific Aims and Hypotheses. 
In the current dissertation research, hematological malignancy patients 
were studied under the hypothesis that chemotherapy-related cognitive 
impairment are attributable to impaired attentional control processes. Due to the 
low temporal resolution of MRI methodologies, overlapping brain regions are 
commonly associated with similar tasks despite being recruited for different task-
related processes and different time scales. In contrast, EEG provides a direct 
measure of electrophysiological neural activity with high temporal resolution, and 
is sensitive to the temporal evolution of attentional control processes. 
Furthermore, although numerous studies have demonstrated self-reported 
changes in quality of life and activities of daily living, there is currently no 
evidence-based measures for evaluating fitness to complete activities of daily 
living in these patients, including automobile driving and resuming/maintaining 
employment. This is particularly troubling, given the link between cognitive 
impairment and increased risk for automobile accidents196–198,224. According to 
the US Department of Transportation, approximately 86% of all workers use their 
primary vehicle to commute to work. Given the increased risk for hematological 
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malignancy patients to experience changes in employment status,26-28 it is critical 
to develop evidence-based metrics for determining if it is safe for hematological 
malignancy patients undergoing chemotherapy to continue driving and 
consequently continue working. 
Hematological malignancy patients were longitudinally studied and 
compared to control groups during a three-month evaluation. Hematological 
malignancy patients were recruited from one of two targeted treatment groups: 
(1) patients scheduled to receive chemotherapy (Ctx+ group); and (2) patients 
receiving supportive care (Ctx- group). Demographically-matched healthy 
controls were recruited (HC group). Ctx- patients served as the chemotherapy 
control group, and HC participants served as the chemotherapy and cancer 
control group. 
All participants underwent a three-month longitudinal study. Ctx+ patients 
completed three separate study visits: (1) any time after diagnosis but prior to 
receiving first treatment cycle (baseline); (2) after one treatment cycle and before 
the second treatment cycle (one month after baseline); (3) after three treatment 
cycles and before the fourth treatment cycle (three months after baseline). Ctx- 
and HC groups underwent three separate study visits at similar time points.  
The specific aims (SA) and hypotheses (H) of this study were: 
SA1. Quantify chemotherapy-related attentional control impairments in 
Ctx+ patients and comparison groups 
H1a. Ctx+ patients will not differ from comparison groups in attentional 
control abilities prior to chemotherapy; following chemotherapy 
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treatment, Ctx+ patients will perform worse than comparison groups 
without cancer or chemotherapy. 
SA2. Quantify the link between chemotherapy-related attentional control 
impairments and electrophysiological measures of attentional control 
in Ctx+ patients and comparison groups 
H2a. Ctx+ patients will not differ from comparison groups in EEG measures 
of attentional control prior to chemotherapy; following chemotherapy 
treatment, Ctx+ patients will differ from comparison groups without 
cancer or chemotherapy. 
H2b. Electrophysiological measures of attentional control will be associated 
with behavioral measures of attentional control (as in H1b). 
SA3. Quantify the effects of chemotherapy-related attentional control 
impairment on complex real-world behavior measured in controlled-
simulations of on-road driving scenarios designed to challenge driver 
attentional control abilities 
H3a. Ctx+ patients will not differ from comparison groups in driving 
performance prior to chemotherapy; following chemotherapy treatment, 
Ctx+ patients will perform worse than comparison groups without 
cancer or chemotherapy. 
H3b. Simulated on-road driving performance will be associated with 
behavioral (as in H1a) and electrophysiological measures (as in H2a) 
of attentional control.  
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CHAPTER 1: METHODS 
Patients 
Patients were recruited within UNMC Division of Hematology/Oncology 
from the clinics of Drs. Vijaya Bhatt, Julie Vose, Matthew Lunning, Sarah 
Holstein, Krishna Gundabolu, Lori Maness, Gregory Bociek, and Philip Bierman. 
Eligible patients were diagnosed with one of the following hematological 
malignancies: Myelodysplasic Syndrome (MDS), Acute Myelogenous Leukemia 
(AML), Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma (MM), Non-
Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), or Chronic 
Myelogenous Leukemia (CML).  
Study Design 
Patients were recruited into one of two cohorts based on their treatment 
plan: 1) patients scheduled to receive chemotherapy (Ctx+ group); and 2) 
patients receiving best support care or no treatment (Ctx- group). Additionally, 
we recruited a third cohort of demographically-matched healthy control (HC) 
participants matched to study patients on age (±5 years), years of education 
(±2 years), race, and gender. Ctx- cohorts served as a comparison group for 
the effects of chemotherapy, and HC cohorts served as a comparison group 
for the effects of both cancer and chemotherapy. Study cohorts completed a 
three-month longitudinal study comprised of three study visits. Participants in 
the Ctx+ group (or comparison groups) completed study visits at the following 
intervals: 1) after diagnosis but prior to chemotherapy treatment (or baseline), 
2) after one treatment cycle (or one-month post-baseline), and 3) after three 
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treatment cycles (or three-months post-baseline). Comparison subjects 
completed assessments at the same intervals.  
Enrollment Criteria 
Inclusion criteria for patients were: 1) between 19 to 80 years of age; 
and 2) normal or corrected-to-normal vision. Inclusion criteria for HC 
participants were identical in addition to being matched to patient 
demographics. Exclusion criteria for patients were: 1) second cancer 
diagnosis in addition to recent study-specific diagnosis (patients with 
localized skin cancer were be excluded); 2) prior radiation or chemotherapy; 
3) baseline cognitive impairment (MMSE score <25); 4) patients who are 
critically ill or require urgent initiation of chemotherapy; and 5) patients with 
any other condition that may not have allowed safe participation in the study 
based on the clinical judgment of the treating oncologist. Exclusion criteria 
for HC participants included any previous cancer diagnosis in addition to all 
exclusion criteria for patients. 
Recruitment 
Patient appointments were identified in the clinic calendar. Eligibility 
status was confirmed with the attending oncologist or with oncology case 
managers. During their clinic visit, physicians or case managers informed 
patients of the broad study goals and procedures. Patients interested in 
participating were then provided verbal and written informed consent, and were 
scheduled for their first study visit. In some cases, due to scheduling limitations, 
patients were asked if they could be contacted by phone to discuss the study 
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further. If interested in participating, these patients were scheduled for their first 
study visit, and written and verbal informed consent were provided prior to 
beginning study procedures. In both cases, the MMSE was administered during 
their first study visit to determine baseline cognitive status per exclusion criteria.  
HC participants were recruited from the Mind & Brain Health Labs 
(MBHL) registry maintained by the Department of Neurological Sciences. The 
MBHL registry provides query options to search for specific demographic 
factors, and are comprised of individuals who have expressed interest in 
participating in research studies. Contacted individuals were informed of the 
study goals and procedures. Interested individuals were scheduled and written 
and verbal informed consent were provided prior to beginning their first study 
visit. 
Study Procedures 
Patients completed a 2.5-hour battery of tests designed to measure 
behavioral and neural mechanisms of attentional control. Broadly, this battery 
involved measuring scalp electroencephalography (EEG) while study 
participants completed computer-based cognitive tasks and driving simulation 
tasks. EEG measures were designed to reveal underlying neural activity 
evoked during cognitive and driving tasks. Clinically-validated measures were 
obtained for comparison, including assessments of visual function, quality of 
life, and neuropsychological performance.  
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Quality of Life Assessment 
The RAND 36-item Short Form Healthy Survey (SF-36) was developed 
during the Medical Outcomes Study (MOS) to measure patient assessed health-
related quality of life225–227. SF-36 has demonstrated good validity227 and 
reliability225 in assessing physical and mental health across patient populations, 
including cancer survivors228,229. SF-36 surveys were completed to assess gold-
standard measures associated with quality of life outlined below. 
SF-36 is comprised of eight subscales designed to measure the following 
constructs226: (1) Physical Functioning – assesses degree to which physical 
activities are limited due to health; (2) Role Limitations (Physical) – assesses 
degree to which performance during work or other daily activities is affected by 
physical problems; (3) Social Functioning – assesses degree to which social 
activities are affected by physical or emotional problems; (4) Bodily Pain – 
assesses degree to which bodily pain is experienced; (5) Mental Functioning – 
assesses degree to which feelings of nervousness and depression are 
experienced; (6) Role Limitations (Emotional) – assesses degree to which 
performance during work or other daily activities is affected by emotional 
problems; (7) Fatigue – assesses degree to which patient feels full of energy or is 
fatigued; (8) General Health – assesses perception of general health.  
SF-36 construct validity has demonstrated ability to discriminate physical 
and mental health problems in patients with medical and psychiatric diseases, 
respectively227. Each construct was assessed on its ability to discriminate 
disease severity (low/high) for medical and psychiatric diagnoses, and 
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incremental disease burden for either medical (high medical severity plus 
psychiatric diagnosis) or psychiatric (high psychiatric severity plus medical 
diagnosis) diagnoses. Physical Functioning construct demonstrated high validity 
for medical severity and incremental (1.0). Role Limitations (Physical) construct 
demonstrated high validity for medical severity (.71) and medical incremental 
(.56). Social Functioning demonstrated strong validity for psychiatric disorder 
(.54), and moderate validity for medical severity (.35), psychiatric severity (.32), 
and psychiatric incremental (.34). Bodily Pain demonstrated moderate validity for 
medical severity (.27) and psychiatric incremental (.34). Mental Health 
demonstrated strong validity for psychiatric severity and incremental (1.0). Role 
Limitations (Emotional) demonstrated strong validity for psychiatric disorders 
(.54), and moderate validity for psychiatric severity (.43) and psychiatric 
incremental (.34). Vitality demonstrated strong validity for medical severity (.67), 
and moderate validity for psychiatric severity (.31) and psychiatric incremental 
(.22). General Health demonstrated strong validity for medical severity (.99) and 
medical incremental (.68), and moderate validity for psychiatric incremental (.26).  
Neuropsychological Assessment 
Four assessments were selected to measure processing speed, attention, 
working memory, and executive control. The following measures were selected 
because they are gold-standard neuropsychological tests that have been used 
extensively to assess cognitive function patients diagnosed with neurological 
diseases. 
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Trail Making Test. Trail Making Test (TMT)230–233 involves drawing lines 
between 25-items randomly distributed on a page, where each consecutively 
drawn line connects two items in ascending order. TMT is comprised of two 
testing formats: (1) Trails A assesses processing and motor speed; and (2) Trails 
B assesses executive control in addition to abilities assessed in Trails A. During 
Trails A, test items are numbers ranging from 1 to 25, and participants complete 
the task by drawing a line between items in ascending number order (e.g. 1-2, 2-
3, 3-4, etc.). During Trails B, test items are numbers (ranging from 1 to 13) and 
letters (ranging from A to L), and participants completed the task by drawing a 
line between numbers and letters in alternating ascending order (e.g. 1-A-2-B-3-
D). Participants were instructed to complete the test as quickly as possible 
without lifting their pencil from the paper. If line segments were completed out of 
order, participants were corrected and an error was noted for each incorrect 
segment. Primary outcome measures for Trails A and Trails B were completion 
time and errors made.  
TMT was designed to measure attention, processing speed, and mental 
flexibility. Reliability estimates for Trails performance are moderate (>.4) 234–236. 
Similar performances in Trails A and Trails B suggest overlapping mechanisms 
are recruited across subtests237–239. Trails performance is correlated with 
performance in other measures of processing speed239,240, visuo-motor 
scanning241, and executive control242,243. Neural correlates of Trails performance 
have been demonstrated in frontal cortex244,245, specifically the dorsolateral 
prefrontal cortex246.  
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Golden Stroop Test. Stroop test247,248 involves rapidly verbalizing a list of 
color names within a 45-second time limit. Color names were limited to blue, red, 
and green. Stroop is comprised of three testing formats: (1) Stroop-W assesses 
word processing speed; (2) Stroop-C assesses color processing speed; and (3) 
Stroop-CW assesses executive control. During Stroop-W, the color name list was 
provided as typed words (i.e. RED, BLUE, GREEN) printed in black ink, and 
participants were asked to read the words as quickly as possible. During Stroop-
C, the color name list was comprised of typed XXXX’s printed in colored ink, and 
participants were asked to name the ink color as quickly as possible. During 
Stroop-CW, the color name list was comprised of typed words in colored ink, and 
participants were asked to name the ink color – not read the word – as quickly as 
possible; words and ink color never matched for any given test item. If 
participants provided the wrong color name, no feedback was provided and the 
item was marked as incorrect. Primary outcome measures for Stroop were 
number completed and errors made. 
Stroop was designed to measure cognitive control over maintaining task 
goals and suppressing habitual responses. Reliability estimates for Stroop 
performance are high (>.7)249, and within-test validity is moderate250. Stroop 
performance is correlated with performance in other measures of processing 
speed251–253, working memory251,254, and fluid intelligence255. Neural correlates of 
Stroop performance have been demonstrated in frontal cortex256,257, specifically 
prefrontal cortex258, lateral prefrontal cortex259–261, and anterior cingulate 
cortex259–261. 
 51 
Paced Auditory Serial Addition Task. Paced Auditory Serial Addition Task 
(PASAT)262,263 involves systematically adding together a sequence of 37 
numbers listed in a recording at a presentation rate of one number every 2.4 
seconds. PASAT measures processing speed and working memory. Participants 
were instructed to add the numbers in pairs, such that each number should be 
added to the number presented just before it. For example, the answer to the 
number sequence 5-7-2-9-6 would be 12-9-11-15 (i.e. 5+7, 7+2, 2+9, 9+6). If 
participants missed the addition of a given number pair, they were instructed to 
continue adding once they heard the next two numbers. If participants incorrectly 
added a given number pair, no feedback was provided and the item was marked 
as attempted but incorrect. Primary outcome measures for PASAT were number 
attempted, number correct, and number incorrect or missed.  
PASAT was designed to measure working memory, divided attention, and 
information processing speed. Reliability estimates for PASAT performance are 
high (>.73) 264,265, and within-test validity is high (>.86) 266. PASAT performance 
is correlated with performance in other measures of information processing267,268, 
attention251,267,269, sustained attention270, divided attention271,272, and working 
memory267,268. Neural correlates of PASAT performance have been 
demonstrated in frontal and parietal cortical regions critical to attention and 
working memory performance273. 
Useful Field of View. Useful Field of View (UFOV)274 is a computer-based 
task that involves rapidly processing information briefly presented within a 
stimulus display and reporting what was processed in a subsequent test display. 
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UFOV is comprised of three testing formats, each named after the cognitive 
function assessed: (1) Processing Speed; (2) Divided Attention; and (3) Selective 
Attention. During the Processing Speed task, a single object was presented 
within a central white box during the stimulus display, and participants were 
instructed to indicate whether the central object was a car or truck during the test 
display. During the Divided Attention task, stimulus displays were identical to the 
Processing Speed stimulus displays with the addition of a single object presented 
in the periphery; the peripheral object was presented in one of 8 locations 
uniformly spaced around an imaginary circle. In the test display, participants 
were instructed to indicate both whether the central object was a car or truck and 
where the object was presented in the periphery. During the Selective Attention 
task, stimulus displays were identical to the Divided Attention stimulus displays 
with the addition of multiple triangle objects designed; test displays were identical 
to the Divided Attention test displays. Task performance was measured by 
systematically changing stimulus display duration based on response accuracy; if 
responses were correct (or incorrect), the subsequent stimulus display was 
presented for a shorter (or longer) duration. Task administration ended when 
responses were correct 75% of the time, resulting in a stimulus detection 
threshold quantified as stimulus display duration. Primary outcome measures for 
UFOV were stimulus detection thresholds for each task. 
UFOV was designed to measure visual function impairments. Reliability 
estimates for UFOV performance are high (>.7) 275, and is sensitive to visual field 
defects224,276 and driving performance277,278. UFOV performance is correlated 
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with performance in other measures of processing speed279–281, attentional 
control281,282, attentional disengagement283, and executive function284. 
Computer-Based Cognitive Tasks 
Two computer-based cognitive tasks were selected to measure attentional 
control function. Capture tasks285–289 measure processes related to inhibitory 
control and disengagement speed; response time is the primary outcome 
measure. This task manipulates multiple stimulus conditions to: 1) examine the 
degree of inhibitory control required to ignore distracting information and 2) 
resolve the speed at which attention can disengage from distracting information. 
Filtering tasks210,290 measure processes related to inhibitory control and storage 
capacity; response accuracy is the primary outcome measure for this task. This 
task manipulates multiple stimulus conditions to examine: 1) how much 
information can be stored in mind and 2) the degree of inhibitory control required 
to ignore distracting information.  
During each task, participants were seated at an eye-to-screen distance of 
58cm from the stimulus presentation display. Stimulus displays were created in 
MATLAB using the Psychophysics Toolbox. Stimulus dimensions are given in 
degrees of visual angle (°) and stimulus colors are given in RGB values.  
Capture Task and Procedures.  
Figure 2A provides an overview of the Capture Task. Each display contained four 
placeholders (1.7°x1.7°; 0.1° line thickness) subtending 3.6° from a black [0,0,0] 
central fixation dot (diameter=.4°), and were rendered against a gray 
[128,128,128] background. Placeholders were fixed at uniformly separated 
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locations centered in each quadrant. In task-irrelevant cue displays, a set of four 
dots (diameter=.2°) were presented at fixed locations around each placeholder, 
each subtending 1.0° center-to-corner for each placeholder. In search displays, 
four Landolt squares (1.0°x1.0°), each with 0.15° line thickness and 0.6° gap 
size, were centered in each placeholder. For each search display, Landolt square 
color (red [256,0,0], green [0,256,0], blue [0,0,256], yellow [256,256,0]), 
orientation (0°, 90°, 180°, 270°), and placeholder assignment were randomly 
sampled without replacement.  
Task procedures for a given trial are depicted in  
Figure 2A. Prior to beginning the experiment, participants were assigned a target 
color (e.g. red). Each trial started with a blank placeholder display for a variable 
inter-trial interval (ITI). ITI values were randomly sampled from a uniform 
distribution ranging from 750-milliseconds to 1500-milliseconds in increments of 
50-milliseconds. Next, the task-irrelevant cue display was presented for 50-
milliseconds. For a given trial, one of three possible cue conditions were 
rendered: (1) Neutral (50% of trials): all placeholder dots were rendered in black; 
(2) Singleton (25% of trials): one set of placeholder dots were rendered in a non-
target color (e.g. green, blue, yellow); (3) Contingent (25% of trials): one set of 
placeholder dots were rendered in the target color (e.g. red). Cue and search 
displays were separated by a blank inter-stimulus interval (ISI) display for a 
randomly sampled duration of 50, 150, 250, or 350-milliseconds. Following the 
blank ISI display, the search display was presented until participants responded 
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with a button press. Participants pressed either the up, down, left, or right array 
keys when the target orientation was 0°, 180°, 270°, or 90°, respectively.  
Participants completed a total of 256 trials. The following conditions were 
counterbalanced across trials: cue condition, cue location, ISI duration, target 
location, and target orientation. Experimenters instructed participants to maintain 
fixation and refrain from initiating blinks or eye movements to the best of their 
abilities (see EEG procedures below). Experimenters instructed participants to 
respond as quickly and accurately as possible.  
Response time (RT) was the primary behavioral outcome measure. For 
each trial, RT was measured as the temporal delay between the onset of task-
irrelevant stimulus display and button press. Aggregate RT distributions were 
inspected individually for each participant. Incorrect trials and trials containing RT 
values more than 3 standard deviations greater than the mean of aggregate RT 
distributions were removed from further analysis1. Remaining RT values were 
then binned and averaged for each cue condition. Response time costs (d’) were 
estimated between cue conditions to determine how cue identity affected 
performance. For any two conditions, response time cost was estimated as: 
RTcost = [(X(1) – X(2))/s(12)2], where X(1) is average RT for condition 1, X(2) is 
average RT for condition 2, and s(12)2 is standard deviation of RT values across 
conditions 1 and 2. Three RT cost comparisons were computed: (1) singleton to 
                                            
1 Of all RT values collected, only 0.88% were more than 3 standard deviations 
outside the mean of aggregate RT distributions. Thus, less than 1% of RT data 
were lost during outlier removal procedures.  
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neutral (singleton d’); (2) contingent to neutral (contingent d’); and (3) contingent 
to singleton (contingent-singleton d’). 
Filter Task and Procedures.  
Figure 2B provides an overview of the Filter Task. Each stimulus display 
contained a central black fixation dot (diameter=.4°) presented against a gray 
[128, 128, 128] background. Cue displays contained a black arrow (1.1°x3.3°) 
that was oriented towards the left or right side of fixation. Memory displays 
contained rectangular stimuli (0.6°x1.7°) that varied in number and color. Target 
items were red [256,0,0], and distractor items, when present, were blue [0,0,256] 
or green [0,256,0]. Target number (1 item, 3 items) and distractor number (0 
items, 2 items) were counterbalanced, producing the following four stimulus 
conditions: (1) Load-1: one red target item and no distractor items; (2) Load-3: 
three red target items and no distractor items; (3) Filter-1: one red target item and 
two distractor items; and (4) Filter-3: three red target items and two distractor 
items. Two sets of task stimuli were presented, where one set was presented to 
the left of fixation and one set was presented to the right of fixation. Stimulus 
locations were constrained to areas outside of a central region (13.1°x8.2°) and 
within a peripheral region (13.1°x16.3°) centered over fixation, and center-to-
center distances between each stimulus were greater than 2.4°. Each set of 
stimulus orientations were randomly oriented at 0°, 45°, 90°, or 135°, with the 
constraint that no two target items were the same orientation and no more than 
two total items were the same orientation. For test displays, a single red test 
stimulus was presented in a randomly sampled target location. Test stimulus 
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orientations were either the same or different with respect to the orientation of the 
probed target item presented in the same location during memory displays. 
Participants were instructed to remember the orientation of each red target 
item presented within the cued side of fixation. Task procedures for a given trial 
are depicted in  
Figure 2B. Each trial started with a blank display for a variable ITI that was 
randomly sampled from a uniform distribution ranging from 750-milliseconds to 
1500-milliseconds in increments of 50-milliseconds. Next, a cue display was 
presented for 200 milliseconds to indicate which set of target items would be 
tested. For trials in which the cue was oriented to the left (or right) side of fixation, 
participants were instructed to remember the left (or right) target items. Next, a 
blank display was presented for variable ISI that was randomly sampled from a 
uniform distribution ranging from 300 to 600 milliseconds in increments of 100 
milliseconds. Blank ISI displays were followed by a 200-millisecond memory 
display. Following a 900-millisecond blank display, a test display was presented 
until a response was made. Participants responded by pressing the “z” or “/” key 
when test and probed stimulus orientations were different or the same, 
respectively. 
Participants completed a total of 256 trials. The following conditions were 
counterbalanced across trials: cue orientation, target number, distractor number, 
and test stimulus orientation. Experimenters instructed participants to maintain 
fixation and refrain from initiating blinks or eye movements to the best of their 
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abilities (see EEG procedures below). Experimenters instructed participants to 
respond as accurately as possible.  
Response accuracy was the primary behavioral outcome measure. For 
each trial, correct and incorrect responses were coded as a 1 and 0, respectively. 
Trial accuracy values were then binned and averaged for each condition. Load-
dependent and filter-related changes in response accuracy were estimated by 
subtracting accuracy in the Load-1 condition from accuracy in the Load-3 and 
Filter-1 conditions, respectively. Thus, load-dependent changes reflect reductions 
in response accuracy associated with storing additional relevant items, and filter-
related changes reflect reductions in response accuracy associated with storing 
additional irrelevant items. 
Driving Simulation 
Driving Simulator. SENSEI (Simulator for Ergonomics, Neuroscience, 
Safety Engineering and Innovation; Figure 3A), a DriveSafety (Salt Lake City, 
UT) RS-600 Research Simulator, is a fully integrated, high performance, high 
fidelity driving simulation system with an authentic automotive cab designed for 
use in ground vehicle design and driving safety research applications. Coupled 
with HyperDrive advanced scene and scenario authoring tools, the SENSEI 
simulation system provides an ideal environment to create purpose-built driving 
scenarios for a wide range of research studies. The RS-600 provides an out-the-
window display environment of 290 degrees with 7 Ultra-HD (3840x2160 each) 
curved LED displays, a full-size automobile cab including windshield, front and 
rear seating compartments, center console, dash and instrumentation, automatic 
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transmission gear select, two side and one center rear view LCD mirrors. The car 
cab is based on a 2004 Ford Focus. This system provides a flexible and 
advanced data collection capability for recording vehicle and driver performance 
measures. 
In addition to measuring general driving performance, participants 
completed two tasks designed to recruit distinct attention abilities. Car following 
tasks291,292 involve maintaining a constant distance relative to a lead vehicle while 
avoiding lead vehicle incursion; this task requires rapidly processing information 
in the environment, suppressing irrelevant information such as pedestrians and 
other vehicles, and enhance relevant information presented by the lead vehicle 
such as braking or accelerating. Visual search task293–297 involves rapidly shifting 
attention within a visual display to find a target item; this task requires rapidly 
processing information, deploying attention between objects, suppressing 
irrelevant information, and enhancing target information within visual displays. 
 Visual Search Task and Procedures. Visual search task required drivers to 
respond with the identity of a red target Landolt square stimulus presented 
among black distractor Landolt square stimuli. Stimulus configurations are 
depicted in Figure 3B. Eight square placeholders (diameter=2.0° visual angle) 
were rendered in white and presented around an imaginary concentric circle 
(radius=7.3°) centered over a .8° white fixation dot. Each placeholder location 
was separated by 22.5°, starting at 22.5° and ending at 337.5°. Landolt square 
stimuli (diameter=1.7°) were rendered with line thickness of .2° and a .6° gap 
centered on one side. Each stimulus display was comprised of 7 black distractor 
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Landolt squares and 1 red target Landolt square. Distractor squares were 
rendered in black with the gap on any one side of a given square, and target 
squares were rendered in red with the gap on either the left or right side of the 
square.  
 Each trial started with the presentation of the square placeholders to cue 
trial initiation. Following a 50-millisecond cueing period, the stimulus display was 
presented until a response was made. Drivers were instructed to indicate 
whether the gap was on the left or right side of the target square by pressing the 
left or right steering wheel button, respectively. Following each response, 
placeholder and stimulus displays were removed for an inter-stimulus interval 
(ISI) period randomly sampled with replacement from values ranging between 1 
and 3 seconds in increments of 1/60th of a second. Target position and target 
direction were counterbalanced across a total of 48 trials.  
Drivers completed visual search task under two conditions: stationary (low 
load) and driving (high load). In the stationary condition, visual search displays 
were presented against a black background and central fixation was visible; in 
the driving condition, visual search displays were presented against the 
naturalistic background (Figure 3B) while drivers traveled along a straight rural 
road. 
 Car Following Task and Procedures. Car following task required drivers to 
maintain a two-car length distance (18 meters) behind a lead vehicle (LV) for 360 
seconds291. LV velocity fluctuated pseudo-randomly across time based on the 
value of a complex signal at time t. Complex signals were created by estimating 
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the weighted linear sum of three randomly sampled sinusoids with a baseline of 
88.5 km/h (55 mph). Each sinusoid had an oscillatory frequency of .033, .083, 
and .117 Hz and an amplitude of 9.770, 3.888, and 2.779 km/h, respectively. For 
each driver, phase values for the second and third sinusoid were randomly 
sampled from a uniform distribution ranging from 0 to 2p radians in increments of 
p/180 radians; phase values for the first sinusoid were constrained such that the 
value of the complex signal at time t=0 would be equal to baseline (88.5 km/h).  
 The car following task was interleaved within a pre- and post-task baseline 
drive for 500 meters at a constant speed of 24.6 m/s. The sequence of events 
leading up to the pre-task baseline drive were as follows. First, drivers were 
instructed to follow the LV at a two-car length distance. Next, the LV was 
triggered to begin modulating its speed, depending on the driver’s following 
distance. If driver distance was greater than 18 meters, LV velocity decreased 
and the driver was instructed to follow at a closer distance. If driver distance was 
less than 18 meters, LV velocity increased and the driver was encouraged to 
maintain that distance. When LV velocity reached 24.6 m/s, the pre-task baseline 
drive began. 
Driving Scenario. Drivers were seated approximately 2.74 meters from the 
central simulator display. Simulator adaptation was implemented first to prevent 
simulator adaptation syndrome; simulator adaptation involved driving through a 
suburban roadway (1.95 kilometers; 40.2 km/h speed limit) and stopping at a 
total of four 4-way intersections. Next, three task segments within the driving 
scenario were completed in the following sequence: (1) the visual search task 
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was completed during the initial segment of a rural highway with an 88.5 km/h 
speed limit; (2) a baseline driving segment was completed on the same rural 
highway following visual search task completion; (3) the LV pulled out in front of 
the driver’s right side of the road; (4) the car following task was completed; (5) 
the LV came to a complete stop, ending the driving scenario. Driving simulation 
took approximately 20 minutes to complete. 
EEG Acquisition and Analysis 
EEG was recorded during cognitive tasks and driving simulation tu study neural 
mechanisms of attention on a millisecond timescale. Three electrophysiological 
components were selected to isolate distinct neural mechanisms of attention. N2pc 
components298–300 measure neural activity associated with spatial shifts of attention; this 
component was used to track whether attention resources are deployed during task-
irrelevant cues during the Capture Task. CDA components210,290,301 measure neural 
activity related to distractor suppression and online storage; this component was used to 
track online storage load and efficiency of filtering irrelevant items during the Filter Task. 
Eye fixation-related potential (EFRP) components302–304 measure information processing 
capacity during naturalistic eye movements; this component was used to track 
information processing capacity during driving simulation. 
EEG was recorded using a NeuroScan NuAmps (Compumedics) digital 
amplifier and silver-chloride electrodes distributed in a fitted elastic cap according 
to the International 10-20 System. EEG was measured from 8 scalp locations 
(O1, O2, PO1, PO2, P3, P4, P7, P8) with a ground reference electrode at the 
AFz site. Electrooculography (EOG) was recorded using a bipolar montage. 
Horizontal EOG (HEOG) was recorded from electrodes placed 1cm outside the 
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lateral canthus of each eye to measure eye movements; vertical EOG (VEOG) 
was recorded from electrodes placed above and below the left eye to measure 
blinks. Impedances of all electrodes were maintained below 10 kW. EEG signals 
were digitized at a sampling rate of 1000 Hz and re-referenced offline to 
mathematically averaged left and right mastoids (A1-A2). Stimulus event triggers 
were sent to the EEG amplifier from the parallel port of a dedicated stimulus 
presentation computer. Continuous EEG measurements were recorded and 
monitored on a dedicated acquisition laptop. Timing delays between stimulus 
presentation and event triggers were measured using an analog photometer and 
corrected during analysis.  
EEG recordings were analyzed using EEGLab305 and ERPLab306 MATLAB 
toolboxes. EEG recordings were high (.01 Hz)- and low (30 Hz)-pass filtered 
using a 2nd order Butterworth filter. Artifact detection routines marked continuous 
EEG segments contaminated by blinks or eye movements in VEOG or HEOG 
recordings, respectively. Blinks were detected when peak-to-peak amplitude 
exceeded 100 µV within a 200-millisecond sliding window and 50-millisecond 
step size. Eye movements were detected when the absolute difference between 
averaged HEOG activity exceeded 100 µV within a 400-millisecond sliding 
window with 10-millisecond step size. EEG segments containing artifacts were 
removed from further analysis.  
Event-Related Potentials. For EEG data collected during Capture and 
Filter Tasks, ERP epochs were extracted after the presentation of each stimulus 
display with a pre-stimulus baseline period of 200 milliseconds. Contralateral (or 
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ipsilateral) waveforms were created by averaging ERP epochs from right 
electrodes (e.g. O2, PO2, P4, P8) when the stimulus cue was presented in the 
left (or right) visual hemifield, and from left electrodes (e.g. O1, PO1, P3, P7) 
when the stimulus cue was presented in the right (or left) visual hemifield. 
Difference waveforms were created for each electrode pair (O1/O2, PO1/PO2, 
P3/P4, P7/P8) by subtracting ipsilateral waveforms from contralateral waveforms. 
Difference waveforms were visually inspected across all electrodes pairs. 
For the capture task, ERP waveforms were measured in PO1/PO2 and 
O1/O2 electrode pairs and inspected 0-400 milliseconds after cue display onset. 
N2pc amplitudes, which are sensitive to spatial shifts of attention towards the 
task-irrelevant cue, were measured by averaging ERP activity from 230 to 280 
milliseconds following cue onset. For the filter task, ERP waveforms were 
measured in PO1/PO2 and P3/P4 electrode pairs and inspected 0-1100 
milliseconds after memory display onset. CDA amplitudes, which are sensitive to 
changes in online working memory storage load, were measured by averaging 
ERP activity from 400 to 1000 milliseconds following memory display onset.  
Eye Fixation-Related Potentials. To study neural correlates of information 
processing during naturalistic eye movements, eye fixation-related potentials 
(EFRP) were measured during driving simulation with unconstrained eye 
movements. EFRP waveforms were measured from EEG recordings during 
baseline driving using the following methods.  
EEG recordings were then extracted 3- to 240-seconds after the driving 
visual search task (Task 2) was completed. HEOG recordings were used to 
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measure eye movements. Saccade offset events were created for timepoints 
meeting all of the following criteria: (1) for 30 milliseconds of HEOG activity 
preceding time t: R2 and b parameter of best fitted regression line were greater 
than .9 and 2.0 uV/ms, respectively; (2) for 150 milliseconds of HEOG activity 
after time t: root mean squared (RMS) of residuals and b parameter of best fitted 
regression line were less than 20 and 2.0 uV/ms, respectively; (3) difference 
between b parameters for both regression lines were greater than 2.0 uV/ms.  
EFRP epochs were extracted 0 to 400 milliseconds after each saccade 
offset event with a 100-millisecond baseline period. Saccade amplitude was 
estimated as the absolute difference between HEOG activity observed -150 to -
100 milliseconds prior to and 0 to 50 milliseconds following saccade offset events 
302. Individual waveforms were analyzed only for epochs with saccade amplitudes 
within the range of 100-400 µV 302 and EEG peak-to-peak amplitudes less than 
160 µV. P1 amplitudes were measured from O1 and O2 electrodes by averaging 
EFRP activity ±50 milliseconds relative to peak amplitude observed 80-120 
millisecond after saccade offset. 
Data Analysis 
 Categorical data were descriptively summarized using frequency and 
percentage tables, and numeric data were descriptively summarized using 
means and standard deviations. Univariate graphs were created for predictor and 
response variables to investigate distributional properties. Between-group 
differences in group demographic characteristics were assessed using chi-
squared tests for categorical variables (e.g. gender) and independent-samples t-
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tests for numeric variables (e.g. age). Between-group differences and within-
group changes in repeated measures were assessed using generalized linear 
mixed models. Models were constructed to account for effects of age and 
education. Repeated measures were modeled using a compound symmetry 
covariance structure. Kenward-Roger degrees of freedom corrections were used 
to account for missing data307. Omnibus statistics were evaluated for effects of 
group and visit, and group-by-visit interactions. Post-hoc within- and between-
group contrasts were assessed by comparing model-derived least square 
means. 
Statistical analyses were performed with SAS Studio 3.6 (SAS Institute 
Inc.). Chi-squared tests were performed using PROC FREQ, and t-tests were 
performed using PROC TTEST. Generalized linear mixed models were 
performed using PROC MIXED, and the PDIFF command was implemented to 
evaluate post-hoc comparisons.  
For the purposes of this dissertation, given its sample size, results were 
interpreted with a p<.20 significance level. This threshold was chosen to identify 
outcome measures to be included in future large-scale confirmatory studies.  
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CHAPTER 2: STUDY SAMPLE 
Sample Characteristics 
45 participants (15 per group) were enrolled into the study between 
November 8, 2016 and September 27, 2017. The complete study sample was 
comprised of participants that were 60.8±14.5 years of age (22-80 years), 47% 
male, 98% Caucasian, 86% right-handed, 64% married, and had 13.9±1.5 years 
of education. Summary statistics for demographic measures are presented for 
each group in  
Table 1. Omnibus between-group analyses did not show evidence of an 
effect for demographic measures of age (F(2,42)=0.30, p=.74), gender (c2(2)=0.53, 
p=.77), education (F(2,40)=1.01, p=.37), handedness (c2(2)=0.93, p=.63), race, and 
marital status (c2(2)=1.33, p=.51). These results indicate that groups were well 
balanced across demographic dimensions. 
MMSE was used to assess evidence for baseline cognitive impairment. 
MMSE performance across groups was 29.2±1.3. Between-group differences in 
MMSE performance did not show an effect (F(2,40)=0.46, p=.64). In addition, 32% 
of participants self-reported normal visual function, and self-reported visual 
function did not show evidence of group effects (c2(2)=0.44, p=.81).  
Across cancer groups (Ctx+, Ctx-), patients were diagnosed with NHL 
(n=16; Ctx+=10, Ctx-=6), MDS (n=7; Ctx+=1, Ctx-=6), AML (n=3; Ctx+=3), ALL 
(n=1; Ctx+=1), CLL (Ctx-=2), and MM (n=1; Ctx-=1). Ctx+ patients received R-
CHOP (n=5), Decitabine (n=3), CHOP, BR (bendamustine rituximab), EPOCH-R 
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(etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and 
rituximab), and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). 
Study participants were prescribed an average of 3 medications, and 
polypharmacy (³4 medications) was noted in 47% of Ctx+ patients, 47% of Ctx- 
patients, and 40% of HC participants. Medications were further evaluated to 
determine the frequency at which study participants were prescribed medications 
known to alter brain and cognitive function (e.g. anti-convulsants, opioids, 
corticosteroids, neurotransmitter antagonists, sedatives). Approximately 47% of 
patients in both Ctx+ and Ctx- groups were taking at least one of these 
medications, compared to only 20% of HC participants; and approximately 27% 
of Ctx+ patients, 20% Ctx- paients, and 7% of HC participants were taking at 
least two of these medications.  
Of 7 patients within the Ctx+ group: 3 patients were taking corticosteroids 
only; remaining patients were taking combinations of: (1) sedative and anti-
convulsant; (2) corticosteroid and sedative; (3) anti-convulsant, corticosteroid, 
and opioid; (4) opioid, corticosteroid, and sedative. Of 7 patients within the Ctx- 
group: 4 patients were individually prescribed an anti-convulsant, opioid, 
corticosteroid, or sedative; 1 patient was taking an opioid and neurotransmitter 
agonist; 2 patients were taking a combination of an anti-convulsant, 
corticosteroid, and sedative with either an opioid or neurotransmitter agonist. Of 
3 participants within the HC group: 2 participants were individually prescribed an 
anti-convulsant or neurotransmitter agonist; 1 participant was taking an opioid, 
neurotransmitter agonist, and sedative.  
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Study Completion 
 30 (67%) study participants completed all study visits. Of the 15 
participants that withdrew from the study, 7 were Ctx+ patients (47% drop rate), 5 
were Ctx- patients (33% drop rate), and 3 were HCs (20% drop rate). No 
significant difference in drop rate was observed between groups (c2(2)=2.45, 
p=.29). Of the 7 dropped Ctx+ patients, 1 was an ALL patient (100% of ALL 
sample), 3 were AML patients (100% of AML sample), and 3 were NHL patients 
(30% of NHL sample). Of the 5 Ctx- patients that withdrew, 1 was a CLL patient 
(50% of CLL sample), 3 were MDS patients (50% of MDS sample), and 1 was an 
NHL patient (17% of NHL sample). Reasons for study withdraw were time 
constraints (n=5), travel constraints (n=2), stroke (n=2), pain (n=1), hospice care 
(n=1), started chemotherapy (n=1), receiving treatment elsewhere (n=1), and 
stopped responding to calls (n=2).  
 Visit 1 completion included 14 Ctx+ patients, 14 Ctx- patients, and 15 HCs 
(96% completion rate); 1 Ctx+ and 1 Ctx- patient withdrew due to time 
constraints. Visit 2 completion included 9 Ctx+ patients, 11 Ctx- patients, and 13 
HCs (73% completion rate); 4 Ctx+ patients withdrew (treatment elsewhere=1, 
time constraints=1, stroke=1, travel constraints=1) and 1 Ctx+ patient missed 
visit 2 due to illness, 3 Ctx- patients withdrew (stroke=1, stopped responding=1, 
time constraints=1), and 2 HCs withdrew (stopped responding=1, time 
constraints=1). Visit 3 completion included 8 Ctx+ patients, 10 Ctx- patients, and 
12 HCs (67% completion rate); 2 Ctx+ patients withdrew (hospice=1, pain=1), 1 
Ctx- withdrew (started chemotherapy), and 1 HC withdrew (travel constrains).  
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 Patients who withdrew from the study were less educated (13.4±1.2) than 
patients who completed the study (14.1±1.6) (F(1,41)=1.99, p=.17). Patients who 
either completed or withdrew from the study did not differ with respect to age 
(F(1,43)=1.55, p=.22), gender (c2(1)=0.40, p=.53), marital status (c2(1)=0.19, p=.66), 
or MMSE score (F(1,41)=.33, p=.57).  
Organization of Results Chapters 
Unforeseen challenges were presented by patients and study methods 
during data collection, particularly for driving simulation measures. Across study 
visits, patients enrolled in the study were unable to complete driving simulation 
due to simulator adaptation syndrome (11%), inpatients unable to travel to lab 
(6%), time constraints during study visit (23%), technical difficulties (4%), and 
lack of driving experience (3%). Due to the volume of missing data, driving 
simulator measures were analyzed as a cross-sectional sample averaged across 
visits with valid data.  
Results chapters were segregated into one chapter comprised of repeated 
measurements collected from cognitive (Specific Aim 1) and electrophysiology 
(Specific Aim 2) methods, and one chapter comprised of cross-sectional 
measurements collected from driving simulation methods (Specific Aim 3).  
Protocol Assessment 
Upon completing the study, patients were asked for any feedback. In 
general, patients provided positive feedback. The most common complaints were 
difficulty of PASAT and filter task, nausea during driving simulation, and traveling 
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demands to and from the study site. 89% of patients agreed to enroll in a 
research registry to continue aiding research efforts in the future. 
Data loss was a primary issue of concern for this study. Reasons for data 
loss were related to unreturned questionnaires, time constraints during visits, 
task difficulty, mobility constraints, technical difficulties, and EEG cap availability. 
In future studies, measures should be taken to reduce data loss. Questionnaires 
should be completed by study participants during their study visit, which should 
minimize data loss for questionnaires. To minimize data loss due to time 
constraints, study participants should be given the option to divide their study 
visits across multiple sessions. PASAT and Filter tasks were the most difficult 
task for patients to complete, though data loss was minimal; future studies should 
evaluate continued difficulty in these tasks to determine whether removal or 
modification is necessary. Technical difficulties were likely due to this being a 
pilot study that required troubleshooting new tools and methods; technical issues 
should continue to be monitored.   
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CHAPTER 3: NEUROCOGNITIVE RESULTS 
Baseline Assessment 
Quality of Life 
Eight outcome measures were obtained from the SF-36 survey: 1) 
General Health – perception of general health; 2) Physical Function – how 
physical activities are limited due to health; 3) Emotional Function – how feelings 
of nervousness and depression are experienced; 4) Social Function – how social 
activities are affected by physical or emotional problems; 5) Role Function – 
Physical – how performance during work or other daily activities is affected by 
physical problems; 6) Role Function – Emotional – how performance during work 
or other daily activities is affected by emotional problems; 7) Fatigue – how much 
patient feels full of energy or are fatigued; 8) Pain – how much bodily pain is 
experienced. Descriptive summaries of quality of life outcome measures are 
presented in  
Table 2.  
Of the 43 participants (Ctx+=14, Ctx-=14, HC=15) who completed 
baseline assessment, 9 failed to return quality of life assessments (Ctx+=4, Ctx-
=4, HC=1). Impaired General Health was reported in 20% of Ctx+ patients, 50% 
of Ctx- patients, and 0% of HC participants (c2(2)=10.7, p=.005). Impaired 
Physical Function was reported in 70% of Ctx+ patients, 30% of Ctx- patients, 
and 14.2% of HC participants (c2(2)=8.23, p=.016). Impaired Emotional Function 
was reported in 30% of Ctx+ patients, 10% of Ctx- patients, and 0% of HC 
participants (c2(2)=5.91, p=.052). Impaired Social Function was reported in 40% 
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of Ctx+ patients, 40% of Ctx- patients, and 14.2% of HC participants (c2(2)=2.79, 
p=.25). Impaired Role Function - Physical was reported by 40% of Ctx+ patients, 
10% of Ctx- patients, and 7.1% of HC participants (c2(2)=4.52, p=.10). Impaired 
Role Function - Emotional was reported by 40% of Ctx+ patients, 20% of Ctx- 
patients, and 0% of HC participants (c2(2)=8.22, p=.016). Pain symptoms were 
reported by 50% of Ctx+ patients, 40% of Ctx- patients, and 14.3% of HC 
participants (c2(2)=4.0, p=.14). 
Significant effects of group were found for General Health (F(2,29)=3.4, 
p=.047), Physical Function (F(2,29)=4.60, p=.018), Emotional Function 
(F(2,29)=4.43, p=.021), Role Function - Emotional (F(2,29)=4.16, p=.026), Pain 
(F(2,29)=3.18, p=.057), and Role Function – Physical (F(2,29)=1.91, p=.17). Post-
hoc comparisons revealed significant differences between Ctx+ and Ctx- groups 
on Physical Function (-35.0±17.2; t29=-2.04, p=.051), Emotional Function (-
13.0±9.0; t29=-1.45, p=.16), Role Function - Physical (-23.7±14.9; t29=-1.60, 
p=.12), and Role Function - Emotional (-14.1±9.6; t29=-1.47, p=.15). Post-hoc 
comparisons revealed significant differences between Ctx+ and HC groups on 
General Health (-20.5±10.2; t29=-2.0, p=.054), Physical Function (-47.1±15.8; 
t29=-2.97, p=.006), Emotional Function (-24.6±8.3; t29=-2.97, p=.001), Role 
Function - Physical (-24.5±13.7; t29=-1.79, p=.084), Role Function - Emotional (-
25.6±8.9; t29=-2.88, p=.007), and Pain (-22.7±9.6; t29=-2.36, p=.025). Post-hoc 
comparisons revealed significant differences between Ctx- and HC groups on 
General Health (-24.9±10.5; t29=-2.4, p=.025) and Pain (-17.9±9.9; t29=-1.81, 
p=.081). 
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Marginally significant effects of age were only found in Social Function 
(F(1,29)=2.22, p=.15). Effects of education were only found in Social Function 
(F(1,29)=4.7, p=.038) and General Health (F(1,29)=1.82, p=.19).  
Neurocognitive 
 Nine outcome measures were obtained from neuropsychological 
assessments: 1) Trails A – processing speed, measured as completion time; 2) 
Trails B – processing speed and executive function, measured as completion 
time; 3) Stroop-W – word processing speed, measured as total number 
completed; 4) Stroop-C – color processing speed, measured as total number 
completed; 5) Stroop-CW – color processing speed and executive function, 
measured as total number completed; 6) Stroop-I – executive function, measured 
as difference between expected and observed Stroop-CW score; 7) PASAT 
Attempts – processing speed and divided attention, measured as total number 
attempted; 8) PASAT Correct – processing speed and divided attention, 
measured as total number correct; 9) UFOV – processing speed, divided 
attention, and selective attention, measured as processing time. Descriptive 
summaries of neurocognitive outcome measures are presented in  
Table 3. 
Of the 43 participants(Ctx+=14, Ctx-=14, HC=15) who completed baseline 
assessment, 1 Ctx+ patient could not complete Stroop-C or Stroop-CW due to 
colorblindness, 4 Ctx+ leukemia inpatients could not complete PASAT or UFOV, 
1 Ctx- patient refused to complete PASAT, and 2 Ctx+ patients could not 
complete UFOV (assessed at different site, technical difficulties).  
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Impaired Trails A performance was found in 7.1% of Ctx+ patients, 0% of 
Ctx- patients, and 6.7% of HC participants (c2(2)=1.6, p=.44). Impaired Trails B 
performance was found in 21.4% of Ctx+ patients, 7.1% of Ctx- patients, and 0% 
of HC participants (c2(2)=4.86, p=.088). Impaired Stroop-W performance was 
found in 14.3% of Ctx+ patients, 7.1% of Ctx- patients, and 6.7% of HC 
participants (c2(2)=.58, p=.75). Impaired Stroop-C performance was found in 
21.4% of Ctx+ patients, 7.7% of Ctx- patients, and 6.7% of HC participants 
(c2(2)=1.71, p=.42). Impaired Stroop-CW performance was found in 21.4% of 
Ctx+ patients, 0% of Ctx- patients, and 0% of HC participants (c2(2)=7.07, 
p=.029). Impaired Stroop-I performance was found in 28.6% of Ctx+ patients, 
15.4% of Ctx- patients, and 6.7% of HC participants (c2(2)=2.59, p=.27).  
Marginally significant effects of group were found for Stroop-C 
(F(2,36)=1.90, p=.16), Stroop-CW (F(2,36)=2.73, p=.08), PASAT Attempts 
(F(2,33)=2.56, p=.09), PASAT Correct (F(2,33)=2.10, p=.14), and UFOV Subtest 3 
(F(2,32)=1.86, p=.17). Post-hoc comparisons revealed significant differences 
between Ctx+ and Ctx- groups on Stroop-C (-6.5±4.3; t36=-1.51, p=.14), Stroop-
CW (-7.0±4.6; t36=-1.54, p=.13), and UFOV (76.6±43.2; t32=1.77, p=.086). Post-
hoc comparisons revealed significant differences between Ctx+ and HC groups 
on Stroop-C (-7.6±4.1; t36=-1.83, p=.076), Stroop-CW (-10.1±4.4; t36=-2.29, 
p=.028), PASAT Attempts (-6.4±2.8; t33=-2.27, p=.03), PASAT Correct (-6.0±2.9; 
t33=-2.04, p=.05), and UFOV (68.1±40.7; t32=1.67, p=.10).  
Significant effects of age were observed in Trails A (F(1,37)=19.9, p<.0001), 
Trails B (F(1,37)=5.87, p=.02), Stroop-C (F(1,36)=19.05, p=.0001), Stroop-CW 
 76 
(F(1,36)=8.64, p=.006), and UFOV (F(1,32)=9.97, p=.004). Marginally significant 
effects of age were observed for Stroop-I (F(1,36)=1.90, p=.18). Significant effects 
of education were observed for Stroop-C (F(1,36)=7.23, p=.011) and Trails A 
(F(1,37)=3.25, p=.08).  
Cognitive Electrophysiology  
Capture Task Review. Six outcome measures were obtained from the 
Capture Task: 1) Neutral RT – processing speed, measured as response time 
during the Neutral condition; 2) Singleton RT – processing speed, measured as 
response time during the Singleton condition; 3) Contingent RT – processing 
speed, measured as response time during the Contingent condition; 4) Singleton 
d’ – bottom-up attentional control, measured as difference in response times 
between Singleton and Neutral conditions; 5) Contingent d’ – top-down 
attentional control, measured as difference in response times between 
Contingent and Neutral conditions; 6) Contingent-to-Singleton d’ – attentional 
control, measured as difference in response times between Contingent and 
Singleton conditions. 
Three outcome measures were obtained from EEG during the Capture 
Task: 1) Singleton N2pc – bottom-up attentional control, measured as N2pc 
amplitude during Singleton condition; 2) Contingent N2pc – top-down attentional 
control, measured as N2pc amplitude during Contingent condition; 3) Contingent-
to-Singleton N2pc – attentional control, measured as difference in N2pc 
amplitude between Contingent and Singleton conditions.  
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Filter Task Review. Six outcome measures were obtained from the Filter 
Task: 1) Load-1 Accuracy – working memory, measured as response accuracy 
during Load-1 condition; 2) Load-3 Accuracy – working memory, measured as 
response accuracy during Load-3 condition; 3) Filter-1 Accuracy – working 
memory, measured as response accuracy during Filter-1 condition; 4) Filter-3 
Accuracy – working memory, measured as response accuracy during Filter-3 
condition; 5) Load-Dependent Accuracy – working memory capacity, measured 
as difference in response accuracy between Load-3 and Load-1 conditions; 6) 
Filter-Dependent Accuracy – attentional control, measured as difference in 
response accuracy between Filter-1 and Load-1 conditions. 
Six outcome measures were obtained from EEG during the Filter Task: 1) 
Load-1 CDA – storage load, measured as CDA amplitude during Load-1 
condition; 2) Load-3 CDA – storage load, measured as CDA amplitude during 
Load-3 condition; 3) Filter-1 CDA – storage load, measured as CDA amplitude 
during Filter-1 condition; 4) Filter-3 CDA – storage load, measured as CDA 
amplitude during Filter-3 condition; 5) Load-Dependent CDA – storage load 
capacity, measured as difference in CDA amplitude between Load-3 and Load-1 
conditions; 6) Filter-Dependent CDA – attentional control, measured as 
difference in CDA amplitude between Filter-1 and Load-1 conditions. 
Of the 43 participants (Ctx+=14, Ctx-=14, HC=15) who completed baseline 
assessment, 5 Ctx+ patients could not complete cognitive electrophysiology 
because they were tested at a different location, 2 participants (1 Ctx-, 1 HC) 
refused to complete the Filter Task, 1 Ctx+ patient could not complete EEG 
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recordings due to limited cap availability, and 1 Ctx- Filter Task EEG data set 
was lost due to technical complications. Descriptive summaries of quality of life 
outcome measures are presented in  
Table 4. 
Grand averaged electrophysiological waveforms are presented in  
Figure 4. N2pc and CDA related activity are clearly shown during capture ( 
Figure 4A) and filter ( 
Figure 4B) tasks, respectively. Larger N2pc amplitudes were observed in 
the contingent cueing condition relative to the singleton cueing condition in the 
capture task, suggesting larger shifts of attention were made towards the task-
relevant stimulus cue, thus replicating previous studies308. Larger CDA 
amplitudes were observed in the Load-3 condition relative to the Load-1 
condition, suggesting larger storage-related neural activity was observed during 
larger memory loads and replicating previous studies290; furthermore, larger 
amplitudes were observed in the Filter-1 condition relative to the Load-1 
condition, suggesting failures of filtering task-irrelevant memory items and 
replicating previous studies210,301. Thus, cognitive electrophysiological measures 
collected here replicated previous studies, confirming the validity of the 
experimental setup. 
Capture Task. Marginally significant effects of group were found for 
Contingent RT (F(2,33)=2.92, p=.07), Singleton d’ (F(2,33)=2.33, p=.11), Contingent 
d’ (F=2.47, p=.10), Singleton N2pc (F(2,32)=3.75, p=.03), and Contingent N2pc 
(F(2,32)=2.64, p=.09). Post-hoc comparisons revealed significant differences 
between Ctx+ and Ctx- groups on Singleton d’ (-.12±.06; t33=-2.04, p=.049) and 
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Contingent d’ (-.14±.07; t33=-1.93, p=.06). Post-hoc comparisons revealed 
significant differences between Ctx+ and HC groups on Contingent RT (-.11±.05; 
t33=-2.38, p=.023), Contingent d’ (-.14±.07; t33=-2.05, p=.049), Singleton N2pc (-
.56±.26; t32=-2.42, p=.041), and Contingent N2pc (-.48±.29; t32=-1.64, p=.11). 
Post-hoc comparisons revealed significant differences between Ctx- and HC 
groups on Contingent RT (-.06±.04; t33=-1.34, p=.19), Singleton d’ (.08±.05; 
t33=1.59, p=.12), Singleton N2pc (-.55±.23; t32=-2.42, p=.021), and Contingent 
N2pc (-.54±.26; t32=-2.13, p=.041). 
Significant effects of age were observed for Neutral RT (F(1,33)=40.2, 
p<.0001), Singleton RT (F(1,33)=38.98, p<.0001), and Contingent RT 
(F(1,33)=42.26, p<.0001), Contingent N2pc (F(1,32)=9.93, p=.04), and Contingent-
to-Singleton N2pc (F(1,32)=16.66, p=.0003). No effect of education was observed 
in any outcome measure. 
Singleton N2pc amplitudes were significantly correlated with Neutral RT 
(r=.45, p=.006), Singleton RT (r=.43, p=.007), and Contingent RT (r=.45, p=.005) 
conditions. Contingent N2pc amplitudes were significantly correlated with Neutral 
RT (r=.63, p<.0001), Singleton RT (r=.61, p<.0001), and Contingent RT (r=.61, 
p<.0001), and Contingent d’ (r=-.32, p=.057). Contingent-to-Singleton N2pc 
amplitudes were correlated with Neutral RT (r=.48, p=.0024), Singleton RT 
(r=.47, p=.003), and Contingent RT (r=.44, p=.006), Contingent d’ (r=-.26, p=.12) 
and Contingent-to-Singleton d’ (r=-.24, p=.15). 
Filter Task. Marginally significant effects of group were found for response 
accuracy during the Load-3 condition (F(2,31)=1.73, p=.19) and Load-Dependent 
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Accuracy Costs (F(2,31)=1.72, p=.20). Post-hoc comparisons revealed significant 
differences between Ctx+ and HC groups on Load-3 accuracy (-.08±.04; t31=-
1.86, p=.073) and Load-Dependent Accuracy Costs (.05±.03; t31=1.72, p=.096), 
and differences between Ctx- and HC groups on Load-Dependent Accuracy 
Costs (.03±.03; t31=1.36, p=.18). Marginally significant effects of age were found 
for response accuracy during Load-1 (F(1,31)=2.58, p=.12), Load-3 (F(1,31)=1.82, 
p=.19), and Filter-3 (F(1,31)=2.06, p=.16) conditions, and CDA during Load-1 
(F(1,29)=1.71, p.20) and Filter-3 (F(1,29)=1.81, p=.19) conditions.  
CDA amplitudes in the Load-3 condition significantly correlated with 
response accuracy in the Load-1 (r=-.45, p=.007), Load-3 (r=-.51, p=.002), Filter-
1 (r=-.45, p=.007), and Filter-3 (r=-.58, p=.0003) conditions, as well as Load-
Dependent Accuracy Costs (r=.23, p=.19). CDA amplitudes in the Filter-3 
condition significantly correlated with response accuracy in the Load-1 (r=-.32, 
p=.061), Load-3 (r=-.32, p=.061), Filter-1 (r=-2.3, p=.20), and Filter-3 (r=-.42, 
p=.01) conditions, as well as Filter-Dependent Accuracy Costs (r=-.27, p=.12). 
Load-dependent CDA amplitudes were associated with larger response accuracy 
in Load-1 (r=-.46, p=.006), Load-3 (r=-.41, p=.017), Filter-1 (r=-.45, p=.0075), and 
Filter-3 (r=-.48, p=.0042) conditions.  
Cross-Platform Correlations  
 Quality of life measures were broadly associated with neurocognitive 
performance (Table 8). Quality of life measures were generally associated with 
Stroop-CW, Stroop-I, and PASAT performance, and Social Function and Role 
Function – Physical were associated with all three of these measures. Most 
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quality of life measures were associated with d’ measures from the Capture 
Task, and both Emotional Function and Social Function were associated with 
response accuracy and Load Accuracy in the Filter Task (Table 9). Most quality 
of life measures were associated with Load-3 CDA amplitudes from the Filter 
Task, and Social Function was associated with many outcome measures from 
the Filter Task (Table 10).  
 Neurocognitive measures were generally associated with by Load-3 
accuracy in the Filter Task (Table 11). In the Capture Task, RT was associated 
with Trails A and Stroop-C performance, and d’ measures were associated with 
Trails B, Stroop-C, and Stroop-CW performance. In the Filter Task, accuracy was 
associated with Trails A and B, Stroop-C, and PASAT performance; Load 
Accuracy was associated with Stroop-W performance; and Filter Accuracy was 
associated with Stroop-W and PASAT performance. Neural cognitive 
electrophysiology measures were generally associated with Stroop-CW and 
Stroop-I performance (Table 12).   
 A correlation matrix of Capture Task and Filter Task outcome measures is 
presented in Table 13. In general, Filter Task response accuracy was associated 
with Singleton d’ and Cue N2pc amplitudes, and Filt-3 CDA amplitudes were 
associated with N2pc amplitudes.   
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Longitudinal Assessment 
Quality of Life 
 Generalized linear models were used to assess the omnibus effects of 
group and interact between group and visit on quality of life outcome measures. 
Model least square means are shown in  
Table 5 and  
Figure 5. A significant group by visit interaction was found for General Health 
(F(4,48.1)=4.65, p=.003). Post-hoc comparisons revealed significant differences 
between Ctx+ and Ctx- groups at T3 (-15.8±11.3; t41.3=-1.40, p=.17), between 
Ctx+ and HC groups at T1 (-17.2±10.4; t37.6=-1.65, p=.11), T2 (-20.3±10.9; t43.5=-
1.87, p=.069), and T3 (-35.7±10.7; t41 = -3.33, p=.0018), and between Ctx- and 
HC groups at T1 (-26.6±10.7; t37.4=-2.48, p=.018) and T3 (-19.9±10.9; t39.2=-1.83, 
p=.075). In the Ctx+ group, significant reductions were observed when 
comparing T1-T3 (-18.4±4.7; t47.6=-3.94, p=.0003) and T2-T3 (-15.6±5.0; t45.9=-
3.12, p=.0032) measurements; in the Ctx- group, significant increases were 
observed when comparing T1-T3 (6.8±4.4; t46.8=1.56, p=.126 )measurements.  
 Significant effects of group were found for General Health (F(2,32.8)=3.82, 
p=.032), Physical Function (F(2,31)=11.9, p=.0001), Emotional Function 
(F(2,22)=7.41, p=.0035), Role Function – Emotional (F(2,32.1)=4.29, p=.022), and 
Pain (F(2,32.3)=5.76, p=.0073). No effect of age was found for any quality of life 
measure (p>.21). Post-hoc comparisons revealed significant differences between 
Ctx+ and Ctx- groups on Physical Function (-35.1±12.8; t32.5=-2.75, p=.0097), 
Emotional Function (-16.4±6.3; t23.4=-2.58, p=.017), and Role Function – 
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Emotional (-12.3±9.2; t32.8=-1.34, p=.19). Post-hoc comparisons revealed 
significant differences between Ctx+ and HC groups on Physical Function (-
58.7±12.1; t31.9=-4.87, p<.0001), Emotional Function (-22.7±6.0; t23=-3.8, 
p=.0009), Role Function – Emotional (-25.4±8.7; t32.4=-2.92, p=.006), and Pain (-
25.6±8.1; t32.6=-3.18, p=.0032). Post-hoc comparisons revealed significant 
differences between Ctx- and HC groups on Physical Function (-23.6±12.1; t29=-
1.96, p=.060), Role Function – Emotional (-13.1±8.8; t31.1=-1.48, p=.15), and Pain 
(-20.6±8.2; t31.5=-2.51, p=.0174).  
Neurocognitive 
 Generalized linear models were used to assess the omnibus effects of 
group and interact between group and visit on neurocognitive performance. 
Model least square means are shown in  
Table 6 and  
Figure 6. Significant group by time interactions were found for performance on 
Trails B (F(4,57.2)=1.96, p=.11), PASAT (F(4,53.8)=2.77, p=.037), and UFOV 
(F(4,60.8)=1.69, p=.16). Between-group post-hoc comparisons revealed significant 
differences between Ctx+ and Ctx- groups: (1) at T1 on Trails B (29.1±16.5; 
t45.1=1.76, p=.084) and UFOV (74.5±34.2; t75.8=2.98, p=.004) ; and (2) at T2 on 
PASAT (-4.7±3.2; t40.7=-1.49, p=.143). Between-group post-hoc comparisons 
revealed significant differences between Ctx+ and HC groups: (1) at T1 on Trails 
B (28.1±16.2; t45.1=1.73, p=.09), PASAT (-6.4±3.0; t37.1=-2.16, p=.038), and 
UFOV (66.2±32.8; t73.3=2.02, p=.047); (2) at T2 on PASAT (-7.3±3.0; t41=-2.42, 
p=.02); and (3) at T3 on PASAT (-4.3±3.1; t41.8=-1.41, p=.165). Between-group 
post-hoc comparisons revealed significant differences between Ctx- and HC 
 84 
groups at T3 on PASAT (-4.9±2.9; t40.6=-1.68, p=.10).  Within-group post-hoc 
comparisons revealed significant changes between T1-T2 measurements in: (1) 
the Ctx+ group on Trails B (-24.9±8.8; t58=-2.81, p=.007) and UFOV (-85.7±31.4; 
t58.4=-2.73, p=.0084); (2) the Ctx- group on PASAT (1.4±1.0; t53.9=1.41, p=.16); 
(3) the HC group on UFOV (-33.3±24.6; t60.2=-1.36, p=.18) and PASAT (1.3±.9; 
t53.8=1.45, p=.15). Within-group post-hoc comparisons revealed significant 
changes between T1-T3 measurements in: (1) the Ctx+ group on Trails B (-
28.9±9.3; t58=-3.12, p=.003), UFOV (-95.6±32.8; t60.2=-1.36, p=.18), and PASAT 
(3.9±1.2; t53.9=3.2, p=.0023); (2) the Ctx- group on Trails B (-11.3±8.4; t57.8=-1.34, 
p=.186); and (3) the HC group on UFOV (-35.6±25.3; t61.1=-1.41, p=.16) and 
PASAT (1.8±1.0; t53.9=1.89, p=.065). Within-group post-hoc comparisons 
revealed significant changes between T2-T3 measurements in: (1) the Ctx+ 
group on PASAT (3.5±1.4; t53.9=2.61, p=.012); (2) the Ctx- group on Trails B (-
14.0±8.5; t55.7=-1.65, p=.105) and PASAT (-1.8±1.0; t53.2=-1.69, p=.098); and (3) 
the HC group on Trails B (-10.3±8.0; t55.9=-1.28, p=.20).  
Significant effects of group were found for performance on Stroop-CW 
(F(2,39)=4.24, p=.022) and Stroop-I (F(2,39.1)=3.73, p=.033). Post-hoc comparisons 
revealed significant differences between Ctx+ and Ctx- groups on Stroop-CW (-
6.6±3.8; t40.2=-1.72, p=.093) and Stroop-I (4.8±3.1; t40.6=1.56, p=.13). Post-hoc 
comparisons revealed significant differences between Ctx+ and HC groups on 
Stroop-CW (-10.6±3.7; t38.8=2.90, p=.006) and Stroop-I (7.9±2.9; t39.2=2.73, 
p=.0096).  
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All neurocognitive measures showed significant effects of time (p<.16), 
demonstrating clear evidence for practice effects. Significant effects of age were 
observed in all neurocognitive measures (p<.02) except PASAT (p=.28). 
Significant effects of education were observed for Trails A (F(1,36.3)=1.81, p=.19) 
and Stroop-C (F(1,35.9)=8.41, p=.0063). 
Cognitive Electrophysiology 
 Generalized linear models were used to assess the omnibus effects of 
group and interact between group and visit on cognitive electrophysiology 
outcome measures. Model least square means are shown in  
Table 7 and  
Figure 7. Significant effects of group were found for Singleton d’ (F(2,31.2)=2.17, 
p=.13), revealing significant differences between Ctx+ and Ctx- groups (-.10±.05; 
t30.4=-2.08, p=.046). Significant interactions between group and visit were found 
for Contingent d’ (F(4,56.6)=1.55, p=.20), Singleton N2pc (F(4,58.8)=1.74, p=.15) and 
Contingent N2pc (F(4,56.7)=3.51, p=.012), Load-1 accuracy (F(4,54.6)=2.65, p=.043), 
Load-3 accuracy (F(4,56.6)=1.79, p=.14), and Filter-1 accuracy (F(4,54.4)=3.14, 
p=.022), Filter-Dependent Accuracy Costs (F(4,57.4)=1.54, p=.20), Load-1 CDA 
(F(4,50.4)=2.70, p=.041), and Filter-Dependent CDA (F(4,56.6)=1.79, p=.14). 
Between-group post-hoc comparisons revealed significant differences between 
Ctx+ and Ctx- groups: (1) at T1 for Contingent d’ (-.15±.08; t57.4=-1.86, p=.069); 
(2) at T2 for Filter-Dependent Accuracy Costs (-.03±.01; t84=-2.53, p=.013), Load-
1 CDA (-.3±.2; t64.3=-1.39, p=.17), and Filter-Dependent CDA (.4±.2; t76.6=1.00, 
p=.05); and (3) at T3 for Filter-Dependent CDA (-.3±.2; t77.1=-1.39, p=.17). 
Between-group post-hoc comparisons revealed significant differences between 
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Ctx+ and HC groups: (1) at T1 for Contingent d’ (-.14±.08; t58.8=-1.85, p=.069), 
Singleton N2pc (-.52±.3; t72.5=-1.71, p=.091), Contingent N2pc (-.5±.4; t59.3=-1.37, 
p=.18), and Filter-Dependent CDA (-.3±.2; t76.8=-1.33, p=.19); (2) at T2 for Filter 
Accuracy (-.02±.01; t84=-1.48, p=.14); and (3) at T3 for Contingent N2pc (.5±.4; 
t63.7=1.49, p=.14) and Filter-Dependent CDA (-.3±.2; t77.5=-1.37, p=.18). Between-
group post-hoc comparisons revealed significant differences between Ctx- and 
HC groups: (1) at T1 for Singleton N2pc (-.5±.3; t68.6=-1.93, p=.057) and 
Contingent N2pc (-.5±.3; t55.4=-1.50, p=.14); (2) at T2 for Filter CDA (-.3±.2; t76.7=-
1.62, p=.11); and (3) at T3 for Contingent N2pc (.5±.3; t55.4=-1.50, p=.15) and 
Load-1 CDA (-.4±.2; t69.2=-1.8, p=.076). Post-hoc comparisons revealed 
significant within-group changes between T1-T2 measurements in: (1) the Ctx+ 
group for Contingent d’ (.11±.06; t54.9=1.72, p=.091), Contingent N2pc (.4±.3; 
t55.9=1.57, p=.12), Load-1 Accuracy (.05±.02; t54=2.57, p=.013), Load-3 Accuracy 
(.05±.02; t54=2.57, p=.013), Load-1 CDA (-.3±.2; t49.3=-1.77, p=.084), and Filter-
Dependent CDA (-.3±.2; t3.7=1.51, p=.14) measurements; and (2) in the HC 
group for Singleton N2pc (-.5±.2; t60.1=-2.18, p=.033) and Contingent N2pc (-.4±.; 
t58=-1.65, p=.10) measurements.  Post-hoc comparisons revealed significant 
within-group changes between T1-T3 measurements in: (1) the Ctx+ group for 
Contingent N2pc (.4±.3; t55.9=1.34, p=.18), and Load-3 Accuracy (.08±.02; 
t54=3.96, p=.0002) measurements; (2) the Ctx- group for Contingent N2pc (.3±.2; 
t58.2=1.29, p=.20) and Load-1 CDA (-.3±.2; t53.6=-1.85, p=.07) measurements; and 
(3) the HC group for Contingent N2pc (-.7±.2; t58=-2.97, p=.004) measurements. 
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Post-hoc comparisons revealed significant within-group changes between T2-T3 
measurements in: (1) the Ctx+ group for Load-1 Accuracy (.03±.02; t54.4=1.33, 
p=.19), Filter Accuracy (.02±.01; t58.7=1.50, p=.14), and Filter-Dependent CDA (-
.6±.2; t53.4=-2.52, p=.015) measurements; (2) the Ctx- group for Contingent N2pc 
(.4±.2; t55.5=1.45, p=.15), Filter-Dependent Accuracy (-.02±.01; t55.6=-1.96, 
p=.055), and Load-1 CDA measurements (-.5±.2; t50.1=-2.82, p=.007); and (3) the 
HC group for Contingent d’ (-.11±.06; t56.4=-1.96, p=.055) measurements. 
Significant effects of age were found for Neutral RT (F(1,32.3)=44.18, 
p<.0001), Singleton RT (F(1,32.5)=42.01, p<.0001), and Contingent RT 
(F(1,32.3)=44.95, p<.0001), Contingent-to-Singleton d’ (F(1,32)=2.53, p=.12), 
Singleton N2pc (F(1,32.6)=2.21, p=.15) and Contingent N2pc (F(1,33.8)=7.64, 
p=.009), Load-3 accuracy (F(1,29.4)=2.75, p=.11) and Filt-3 accuracy (F(1,28.2)=2.42, 
p=.13), Load-1 CDA (F(1,24.6)=3.26, p=.083), Load-3 CDA (F(1,27.8)=15.76, 
p=.0005), and Filt-3 CDA (F(1,29.2)=2.28, p=.14), and Load-Dependent CDA 
(F(1,22.1)=12.63, p=.0018). 
Comment on Modeling Outcomes 
 Multiple outcome measures were evaluated for evidence of 
chemotherapy-related changes. Distributional assumptions of outcome measures 
were confirmed by inspecting model residual plots, which revealed no detectable 
deviation from normality. To overcome potential limitations imposed by missing 
data, the same modeling procedures were run using data only from research 
participants that completed all three study visits. Comparing complete and 
reduced data sets, the same statistical omnibus pattern was observed for all 
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outcome measures, with the exception of Trails B and Filter-Dependent 
Accuracy. For outcome measures replicating the omnibus pattern, all post-hoc 
contrasts replicated with the following exceptions: comparisons between Ctx+ 
and Ctx- groups at T2 for General Health and PASAT, and at T3 for General 
Health and Contingent N2pc; comparisons between Ctx+ and HC groups at T1 
for Filter-Dependent CDA, and at T3 for PASAT; comparisons between T1-T2 in 
Ctx+ patients for General Health, and PASAT for Ctx- patients; and comparisons 
between T1-T3 for Filter-Dependent CDA. Differences observed in the reduced 
data set may reflect either a reduction in power or differences in patient 
characteristics for those patients who dropped out following T1 measurements. 
For example, study participants who dropped from the study were statistically 
less educated from those who remained in the study.   
 
Discussion 
Three primary patterns of results were observed across significant findings 
(Figure 9): 1) Chemotherapy effects – Ctx+ patients showed impairment after 
initiating chemotherapy; 2) Cancer effects – Ctx+ and Ctx- patients showed 
greater impairment than HC; 3) Disease Severity effects – Ctx+ patients showed 
greater impairment than Ctx- and HC groups. Of particular importance, a priori 
hypotheses predicted Chemotherapy effects across all outcome measures. 
Although results from some outcome measures were similar to one of the 
primary patterns, many outcome measures showed results that were consistent 
with more than one primary pattern. For example, some outcome measures 
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showed evidence for both cancer and chemotherapy effects, in which both Ctx+ 
and Ctx- patients showed greater impairment than HC participants, and Ctx+ 
patients showed an additional increase in impairment that was not observed in 
Ctx- patients. Results are summarized according to these patterns. 
 Chemotherapy effects were noted when only Ctx+ patients showed 
declines in performance across consecutive study visits, suggestive of 
chemotherapy-specific changes. Chemotherapy effects were observed: 1) from 
T1-T2 in Filter-Dependent Accuracy and Contingent N2pc; and 2) from T2-T3 on 
Filter-Dependent CDA, Contingent N2pc, and General Health. Interestingly, 
these outcome measures were not predictive of each other. 
 Cancer effects were noted when both Ctx+ and Ctx- patients showed 
greater impairment than HC comparisons. Cancer effects were observed: 1) at 
each study visit in Role Function – Emotional, Physical Function, and Pain; 2) at 
T1 in Singleton N2pc, Contingent N2pc, and General Health; 3) at T2 in General 
Health; and 4) at T3 in PASAT. Of these measures, associations were only 
observed between Physical Function and PASAT performance.  
 Disease severity effects were noted when Ctx+ patients showed greater 
impairment than both Ctx- and HC groups at least during baseline assessment, 
suggestive of selective impairments in Ctx+ patients unexplained by 
chemotherapy treatment. Disease severity effects were observed: 1) at each 
study visit in Stroop, Physical Function, Role Function – Emotional, and 
Emotional Function; 2) at T1 in Trails B, UFOV, Contingent d’, and Filter-
Dependent CDA; and 3) at T2 in PASAT. In contrast to other effects, outcome 
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measures showing disease severity effects were highly inter-related. Both 
Physical Function and Emotional Function were associated with Trails B, PASAT, 
and Contingent d’; Role Function – Emotional was associated with Stroop and 
Contingent d’; Trails B was associated with Contingent d’, and Stroop was 
associated with Contingent d’. 
 In summary, Chemotherapy effects were observed in measures of 
attentional control; Cancer effects were observed in measures of attentional 
control and divided attention; and Disease Severity effects were observed in 
measures of executive function, selective attention, and attentional control.  
Alternative explanations for study results should be considered. First, both 
cancer groups were prescribed medications known to affect brain and cognitive 
function, which may explain why cancer groups performed worse on 
neurocognitive measures across study visits. Second, Ctx+ patients were likely 
experiencing anxiety in anticipation of chemotherapy initiation; although anxiety 
measures were not collected here, anxiety may explain worse performance in 






CHAPTER 4: DRIVING SIMULATION RESULTS 
(This chapter was reformatted from a manuscript submitted for publication in the 
Transportation Research Records: Journal of the Transportation Research Board) 
Results 
Study Enrollment 
45 study participants were enrolled in the study at the time of analysis. Of 
enrolled participants, 17 participants did not complete driving simulator 
procedures due to the following reasons: simulator discomfort (n=4), dropped out 
prior to initiating study procedures (n=2), acute leukemia patients who could not 
be transported to driving simulator (n=4), technical difficulties with EEG (n=1), 
research assistant error (n=1), patient not wearing EEG during driving simulation 
(n=1), or ongoing study participation (n=4).  
 Of the 17 participants who did not perform the current study, 88% were 
HM patients (n=15) and 12% were HC participants (n=2). Of the 15 HM patients 
who did not perform the current study, 60% were receiving chemotherapy (n=9) 
and 40% were receiving best supportive care (n=6). Of the 4 participants with 
simulator adaptation syndrome, 50% were Ctx+ patients, 25% were Ctx- patients, 
and 25% were HC participants.  
Study Patient Characteristics 
One HM patient was excluded from analysis due to anisometropia, 
resulting in 14 HM patients and 13 HC comparisons that were included in the 
current study. HM patients were diagnosed with myelodysplastic syndrome (n=4), 
non-Hodgkin lymphoma (n=9), or multiple myeloma (n=1). Of the 14 HM patients 
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that completed task procedures, 6 were receiving chemotherapy and 8 were 
receiving best supportive care. HM and HC groups did not differ along 
demographic dimensions of gender (HM: 50% female; HC: 46% female; c2=0.04, 
p=.84), age (HM: 61.6±14.0; HC: 58.0±17.0; t25=.61, p=.55), or years of 
education (HM: 13.8±1.8; HC: 14.4±1.7; t25=.90, p=.38).  
Task Performance 
Visual search performance was faster during baseline (989 ±302 
milliseconds) compared to driving (1027 ±316 milliseconds) conditions (t26=1.79, 
p=.08). HM and HC groups demonstrated comparable visual search 
performances in both baseline (HM=1055 ±380, HC=917 ±173; t25=1.20, p=.24) 
and driving (HM=1105 ±386, HC=945 ±56; t25=1.33, p=.20) conditions. Driving 
load-dependent differences in response times did not differ between HM (49 
±131 milliseconds) and HC (28 ±94 milliseconds) groups (t25=.48, p=.64). 
Although between-group differences did not show evidence of statistical 
significance, odds of HM patients to show larger load-dependent differences in 
response times were 2.9 times the odds of HC patients. 
Saccade Behavior 
Previous EFRP studies have shown P1 amplitudes are more reliable 
following larger saccades 302. Therefore, saccade events were submitted for 
analysis only if they fell within the amplitude range of 100-400 µV. HM and HC 
groups did not differ from each other in either total number of saccade events 
(HM: 148.4±97.1; HC: 158.1±111.4; t25=.24, p=.81) or average saccade 
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amplitude (HM: 179.0±16.8 µV; HC: 183.5±22.0 µV; t25=.61, p=.55). These 
results are suggestive of similar saccadic behaviors between HM and HC groups. 
EFRP 
Grand-averaged EFRP waveforms for HM and HC groups are depicted in  
Figure 8A. Both groups demonstrated a clear positive deflection in EFRP 
amplitude in O1/O2 electrodes approximately 101 milliseconds after saccade 
offset consistent with P1 component. Average P1 amplitudes were larger for HC 
(2.51±1.60 µV) compared to HM (1.43±2.37 µV) groups (t25=1.37, p=0.18; 
Cohen’s d=0.54;  
Figure 8C). Using a median-split of P1 amplitudes to partition individual drivers 
into high or low amplitude groups, odds of HM patients being in the low amplitude 
group were 4.1 (CI: 0.81-20.2) times to the odds of HC participants being in the 
low amplitude group. These results suggest the capacity of information 
processing following saccadic eye movements is reduced in HM patients 
compared to HC participants.  
 Slower response times during visual search tasks have important 
implications for detecting hazardous events. Next, we examined the relationship 
between post-saccadic information processing and behavioral costs sustained in 
visual search performance completed during driving relative to baseline 
performance. Using a median-split of response time differences, we noted 
different EFRP patterns between drivers showing low and high costs ( 
Figure 8B). During the P1 window, we observed larger amplitudes in the drivers 
sustaining smaller behavioral costs (r=-0.44, p=.022). P1 amplitudes were larger 
for the low-cost group (2.85±1.95 µV) compared to the high-cost group 
(1.11±1.87 µV; t25=2.37, p=.03; Cohen’s d=0.91). Indeed, odds of low-cost 
drivers showing larger P1 amplitudes were 20.2 (CI: 2.80-144.93; c2=10.8, 
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p=.001) times the odds of high-cost drivers, suggesting lower P1 amplitudes may 
be associated with greater sensitivity to cognitive load on visual search behavior.  
 Next, we examined the relationship between behavioral costs and P1 
amplitudes separately for HM and HC groups. We found that the odds of low-cost 
drivers showing larger P1 amplitudes were 31.9 (c2=6.64, p=.01) and 10.5 
(c2=3.26, p=.07) times the odds of high-cost drivers in HM and HC groups, 
respectively. These results demonstrate post-saccade information processing 
capacity is similarly reduced across groups for drivers slower to detect targets 
within visual search displays.  
Discussion 
HM patients are at risk for impaired processing speed and attention 41,49,76, 
and impaired visual attention contributes to increased risk for vehicle crashes 196. 
Consequently, this pilot study used state-of-the-art driving simulation and EEG to 
test the hypothesis that visual attention is impaired in cancer patients with HM. 
EFRP activity, an electrophysiological measure of information processing 309–312, 
showed promising evidence for reduced information processing in HM patients 
within 150 milliseconds of saccade termination. Amplitudes of the P1 EFRP 
component were reduced in HM compared to HC drivers. In contrast, HM and 
HC groups did not differ in saccade frequency or saccade magnitude. Thus, HM 
patients differed from HC comparisons in neural information processing and not 
in saccade measures. 
We also found a relationship between driving load-dependent declines in visual 
search performance and P1 amplitudes ( 
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Figure 8B, D). Previous studies show that older drivers are slower to respond 
and use more eye movements during visual search within traffic scenes 313. 
Patients with glaucoma, an age-related eye disease characterized by peripheral 
visual field loss, are slower to respond and deploy less efficient eye movements 
during visual search 314. These behavioral patterns may reflect recruited auxiliary 
mechanisms to compensate for reduced information processing capacity in 
posterior cortex 101. In the context of studies demonstrating age- and disease-
related changes in visual search performance 313,314, increased saccade 
frequency may be an auxiliary mechanism for overcoming reduced neural 
information processing capacity by sampling driving scenes more frequently and 
consequently boosting signal-to-noise ratio. The current work shows reduced 
neural information processing capacity (i.e. P1 amplitudes) in drivers showing 
greater load-dependent declines in visual search performance, which was more 
prevalent in HM drivers. Our findings promote further investigations to elucidate 
the relationship between reduced neural information processing capacity and 
saccade behavior in HM patients during more complex visual search scenes. 
We find that spatial loci of fixation and attentional resources are 
separable. This recalls the situation of inattentional blindness, 315,316 in which 
observers fail to detect an unexpected object within the locus of fixation (63, 65). 
These findings militate against exclusive reliance on eye-tracking methods to 
study visual attention. Further investigation is needed on relationships between 
disease-related changes in saccade behavior and information processing metrics 
in visual cortex. Combining eye-tracking and EFRP methods 317,318 promises to 
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advance the understanding of how disease-related changes in attention translate 
to failures in hazard detection while driving.  
We found no difference between HM and HC groups in visual search 
performance. One possible explanation is that our stimulus display promoted 
highly efficient visual search performance. Visual search efficiency has been 
shown to be affected by target and distractor similarity 319. Displays comprised of 
low target-distractor similarity (e.g. red target, black distractors) and high 
distractor-distractor similarity (e.g. all black distractors) promote efficient, such 
that competing distractors fail to impose response time costs. Conversely, 
displays increasing in target-distractor similarity and decreasing in distractor-
distractor similarity result in inefficient search, such that competing distractors 
impose response time costs that increase with distractor number. Thus, more 
complex visual search displays demand focused attention to discriminate 
between target and distractor search elements 293,296. Here, our results indicate 
that performance is indistinguishable between cancer patients and healthy 
comparisons during efficient visual search. Future studies are needed to 
determine whether performance during visual search within complex displays is 
impaired in cancer patients. 
EFRP measures can help probe how the brain processes information 
before, during, and after eye saccades. First, pre-saccadic shifts of attention 
enhance perceptual processing of locations and features present in the saccadic 
targets 320,321. Second, saccadic suppression inhibits neural activity in low-level 
visual regions during eye movements 322–324. Third, information processing is 
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enhanced immediately following saccade offset 325,326. Importantly, most of what 
we know about the neural mechanisms of visual attention during saccades has 
been gained through studies of non-human primates. EFRP studies in human 
subjects engaged in real-world relevant tasks may complement and advance our 




 Results from this study provide several novel contributions to the state-of-
the-science in chemotherapy-related cognitive impairment. First, behavioral 
correlates of attentional control were evaluated using cognitive tasks designed to 
probe specific attention functions. Second, neural correlates of attentional control 
were measured using EEG methods designed to dissect specific attention 
functions as they emerge in near-real time. Third, both behavioral and neural 
correlates of attentional control were evaluated in a real-world setting using 
simulations of naturalistic driving. As discussed below, these findings provide a 
foundation for better understanding the biological mechanisms of chemotherapy-
related cognitive impairment. Although these findings represent important 
contributions to the field, several study limitations should be noted. Of particular 
importance, a complete interpretation of these results is constrained by the small 
sample size, heterogeneous cancer diagnoses and chemotherapy protocols, and 
missing data and patient drop out. Further large-scale confirmatory studies are 
therefore needed to fully appreciate the implications of these findings. 
Nevertheless, the following sections address initial study implications. 
Contextualizing Study Results 
Quality of life impairments have been demonstrated in hematological 
malignancy patients prior to treatment33,46–49 and during treatment47–49. Here, 
cancer-related impairments in physical function, pain, and role function affected 
by emotional limitations were observed across study visits; chemotherapy-related 
reductions in general health were observed during treatment; and disease 
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severity-related impairments in chemotherapy patients were noted across study 
visits. This study failed to replicate previous studies showing fatigue effects prior 
to and during treatment47–49. There are two possible reasons for this difference. 
Excluding factors contributing to study limitations, the most likely explanation is 
differences in fatigue assessments. Previous studies used either the EORTC47,48 
or BFI49, whereas the current study used the SF-36. Critically, each of these 
measures differ in how far back in time patients are asked to assess their 
symptoms. SF-36 assess fatigue symptoms over the past 4 weeks, whereas the 
BFI327 and the EORTC328 assess fatigue symptoms over the past 24 hours and 
the past week, respectively. Thus, differences in the timescale of assessment 
most likely explains differences between the current and previous studies on 
fatigue assessments. Nevertheless, the current study largely replicates previous 
quality of life studies of hematological malignancy patients. 
 Cognitive impairments have been noted in hematological malignancy 
patients prior to treatment49,70 and  during treatment49,55,70. These studies found 
impairments primarily in the domains of memory49,55, executive function49,55, and 
processing speed49. Here, cognitive performance was impaired in the domains of 
executive function (Stroop-CW, Stroop-I) and working memory (PASAT) both 
prior to and during chemotherapy.  The current study therefore replicates 
previous studies showing impaired executive function prior to and during 
treatment. In contrast, this study failed to replicate previous studies showing pre-
treatment impairments in Trails A49. The study sample demonstrating pre-
treatment effects on Trails A was comprised of 65% MDS and 35% AML patients. 
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In the current study, the chemotherapy group was comprised of only 7% MDS 
and 20% AML patients. Differences in patient diagnoses is most likely 
explanation for these differences, though further study is required to evaluate 
disease-specific differences in pre-treatment cognitive impairment in 
hematological malignancies.  
 To date, only cross-sectional studies have examined differences in neural 
function in hematological malignancy. These studies demonstrated reliable 
differences between chemotherapy and non-chemotherapy groups in PET 
activity within the dorsal-attention and central-executive networks52,96. One study 
showed that PET activity in these networks correlated negatively with number of 
chemotherapy cycles and positively with time since chemotherapy, suggesting 
chemotherapy patients experience acute impairment followed by recovery of 
normal brain metabolism following treatment52. Another study demonstrated 
distinguishable multivariate patterns of network activity between chemotherapy 
and non-chemotherapy groups, suggesting chemotherapy functionally alters 
network activity differently from cancer-related effects96. In the current study, 
cognitive functions governed by dorsal attention and central executive networks 
were examined using N2pc and CDA amplitudes, respectively. Prior to treatment, 
neural activity showed cancer-related impairments in both N2pc and CDA 
activity. During treatment, neural activity showed: (1) both cancer- and 
chemotherapy-related changes in N2pc amplitudes; and (2) chemotherapy-
related changes only in CDA amplitudes.  
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 Results shown in the current work replicates and extends previous cross-
sectional studies in three major ways. First, this study examined 
electrophysiological measures of attention and executive functions prior to and 
following treatment, providing a longitudinal assessment of associated 
chemotherapy-related changes in a novel neural measure. These findings 
confirmed cancer- and chemotherapy-related changes in neural measures of 
attention and executive function. Second, this study confirmed previous study 
results showing patterns of PET activity in central executive network that were 
dissociable chemotherapy patients and comparisons52,96. Here, CDA amplitudes 
were affected differently in chemotherapy and non-chemotherapy cancer 
patients, which were both different from healthy comparisons. Third, this study 
confirmed previous study results showing different trends in patterns of PET 
activity within the dorsal attention network96. Here, we showed N2pc amplitudes 
differed between chemotherapy patients and comparison groups, though not in a 
predictable way. Thus, further work is required to better understand how dorsal 
attention network properties change with chemotherapy, and how dorsal 
attention and central executive network properties change and interact with 
cancer and chemotherapy. 
This study is the first to evaluate how cognitive impairment in cancer 
patients maps onto real-world task demands studied in high-fidelity simulated 
driving settings. We used driving simulation, eye movement, and EEG measures 
to study visual attention and driving in cancer patients with HM. Lower EFRP 
activity following saccade offset was observed in drivers showing greater 
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impairment in visual search performance while driving, consistent with previous 
studies showing EFRP activity is associated with task performance. We found 
similarly reduced EFRP activity in drivers diagnosed with a HM. In contrast, 
measures of saccade behavior such as frequency and magnitude were unrelated 
to both cognitive function and disease status. These results support a functional 
dissociation between saccade behavior and post-saccade information processing 
during driving and may serve as a neural measure of impaired information 
processing in diseased and cognitively impaired populations. These findings are 
particularly important for future work, given the relationship between impaired 
visual attention and increased risk for vehicle crashes 196. Furthermore, these 
results confirm that an increased risk for impaired processing speed and 
attention in hematological malignancy patients41,49,76 translates to impaired 
processing capacity in a real-world driving setting.  
Comparison to Other Cancer Populations 
 In comparison to the limited studies of chemotherapy-related cognitive 
impairment in hematological malignancies, numerous studies have been 
conducted in other cancer populations. For the purposes of comparison to the 
current study, only those studies with a longitudinal design and comparison 
groups are reviewed here170–172,174,175,177,183–187,189,329–331. Prior to treatment, 
behavioral studies demonstrated cancer-related impairments in processing 
speed170–172,330,331, working memory171,330,331, and verbal memory174,330,331; 
functional MRI studies have shown cancer-related differences in cortical activity 
within frontal and parietal regions187, as well as greater spatial variance within the 
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executive function network175,177. Up to 3-months following treatment, previous 
behavioral studies have demonstrated chemotherapy-related impairments in 
processing speed183,184,329, working memory183, executive function171,183,184, and 
verbal memory171; structural MRI studies have shown chemotherapy-related 
reductions in gray matter volume within frontal184186189, parietal184189, and 
temporal184186189 cortical regions; functional MRI studies have shown 
chemotherapy-related changes in task-based cortical activity within frontal, 
parietal, and temporal regions187. Askren and colleagues175 studied network-level 
activity in breast cancer patients, and found no difference in spatial variance 
within the executive function network despite finding baseline differences 
between groups prior to treatment. These results are similar to the pattern 
observed in the filter CDA effects reported here, in which Ctx+ and Ctx- groups 
demonstrated larger CDA effects prior to treatment, but then Ctx+ patients 
showed a reduction in CDA effect at one-month followed by an increase in CDA 
effect at three-months. Whether this pattern reflects underlying chemotherapy-
related changes in executive function network activity demands further study.  
 Results shown in the current work replicate and extend studies performed 
in other cancer populations in several important ways. First, this work contributes 
to a growing body of literature demonstrating cancer- and chemotherapy-related 
cognitive impairment in hematological malignancies, an understudied cancer 
population. Second, this work examined neural correlates of cognitive function in 
a longitudinal study design, which is lacking in studies of hematological 
malignancy; in contrast, breast cancer studies in particular have focused on 
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longitudinal designs with appropriate comparison groups to elucidate the roles of 
tumor biology and chemotherapy toxicity in cognitive impairment observed in 
cancer patients. Third, cognitive and neural measures examined here recruit 
frontal and parietal cortical regions that have shown both structural and functional 
changes in other cancer populations, suggesting overlapping mechanisms. 
Fourth, this work used an experimental study design to evaluate potential 
changes in driving performance, a critical activity of daily living. Finding evidence 
for the potential impact of chemotherapy on information processing capacity and 
on-road hazard detection demands further studies into whether cancer patients 
may be public health and safety concern that demands mitigation through novel 
intervention and technology development. 
Attentional Control Mechanisms 
 In this section, basic research on attentional control and its underlying 
neurophysiological and neurochemical mechanisms are reviewed. Once the 
theoretical framework for attentional control mechanisms is established, I 
transition in the next section (Biological Mechanisms of Cognitive Impairment) to 
contextualizing putative biological mechanisms of cancer- and chemotherapy-
related cognitive impairment within the framework of attentional control 
mechanisms. Together, these sections motivate future research into specific 
interactions between tumor biology, treatment toxicity, and attentional control 
mechanisms. 
 Attentional control broadly refers to the ability to efficiently and effectively 
execute basic attention processes during complex cognitive tasks. Four basic 
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attention processes are traditionally distinguished: (1) focusing limited-capacity 
attentional resources on most relevant information332; (2) selecting information to 
be focused on by biasing attention toward relevant information among competing 
irrelevant information192; (3) improving the quality of selected information by 
facilitating sensory processing of information-specific neural activity333,334; and (4) 
sustaining attentional resources over selected information or potential sources of 
information335–337. Attention processes can be deployed towards information 
externally (i.e. in the environment) or internally (i.e. in mind) present with respect 
to the observer193,194. Thus, attentional control must effectively manage a limited 
pool of resources by selecting and enhancing the processing of only most 
relevant information over a sustained period of time.  
Attentional control coordinates attention processes through competitive 
interactions between dorsal and ventral attention networks. Dorsal attention 
networks are involved in disengagement of attention from and orienting of 
attention toward information179,202, and are primarily distributed along frontal and 
parietal cortical regions including: superior frontal gyrus (SFG), medial frontal 
gyrus (MFG), intraparietal sulcus (IPS), lateral occipital gyrus (LOG), superior 
temporal sulcus (STS), and posterior cingulate (PC)179. Ventral attention 
networks are involved in selectively modulating information-specific neural 
activity in sensory cortex179, and are primarily distributed along occipital and 
parietal cortical regions including: inferior frontal gyrus (SFG), precentral gyrus 
(preCG), postcentral gyrus (postCG), superior parietal lobule (SPL), and 
cuneus179. Cortical regions distributed across dorsal and ventral attention 
 106 
networks show both structural and functional dissociation based on measures of 
white matter tractography338 and resting-state fMRI339,340. Thus, dorsal and 
ventral attention networks demonstrate putative roles for information selection 
and enhancement, respectively. 
Orienting of attention results primarily from bi-directional patterns of front-
parietal neural activity within the dorsal stream202,341–344: (1) voluntary control 
through top-down frontal-to-parietal modulation344,345; or (2) involuntary control 
through bottom-up parietal-to-frontal modulation344. Top-down modulation 
selectively increases the magnitude of signal available in population-level neural 
activity specific to the attended information346–350, effectively communicating 
greater neural activity associated with relevant information at the expense of 
irrelevant information351,352. Theoretical models propose that information-specific 
activity is better communicated within and between cortical regions by selective 
rhythmic synchronization of neuronal activity coding for relevant 
information204,353,354. Voluntary control of attention is disrupted when a salient 
stimulus (e.g. car horn) captures attention, resulting in an involuntary response to 
the novel stimulus355–358. Bottom-up modulation effectively increases the 
magnitude of neural activity associated with the salient stimulus in sensory 
cortex359, which is amplified in parietal cortex360,361 and subsequently propagated 
to frontal cortex362,363. Theoretical models propose that patterns of neural activity 
coding for information-specific features and spatial locations represent distinct 
cortical processes364,365. Thus, where and what attention is directed towards 
depends on interactions between voluntary and involuntary control mechanisms. 
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Competitive interactions between dorsal and ventral attention networks 
collectively determine the locus of spatial attention and the quality of attended 
information296,366–368. Although the dorsal attention network activates top-down 
control over the ventral attention network to select and enhance goal-relevant 
neural activity, salient or unexpected information engage the ventral attention 
network and activate bottom-up control over the dorsal attention network to orient 
attention to the salient information369–372. Furthermore, bottom-up control over the 
dorsal attention network is more likely to occur when the salient information is 
relevant to goals of the observer (e.g. hearing a car horn while either driving or 
watching a movie) 286,289. Conversely, information processing in regions activated 
by bottom-up control is inhibited following the salient stimulus373, reflecting 
disengagement of dorsal attention network from bottom-up control and 
subsequent suppression of activated regions within the ventral attention network.  
Attentional control mechanisms are also critical to eye movements (or 
saccades) 374. According to this model, the same network of brain areas are 
activated for saccades and spatial attention342,375,376, which coordinate to shift 
spatial attention prior to saccades. Numerous studies suggest that frontal eye 
fields (FEF), superior colliculus (SC), and substantia nigra are integral to 
coordinating spatial attention and saccades377–380. Prior to saccades, spatial 
attention disengages from the current location, orients to a new location, and 
selectively modulates the new target of attention98. Supporting this hypothesis, 
neural activity is biased towards saccade targets prior to initiating the 
saccade203,381–384, and target detection and discrimination is better at saccade 
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terminations385,386. Thus, attentional control is critical to attention processes 
within and between eye fixations. 
Long-range communication of information-specific neural activity within 
and between dorsal and ventral attention networks depends on neurotransmitter 
systems to propagate action potentials across the synaptic cleft. 
Neuromodulation of dorsal and ventral attention networks has been well-
documented in dopaminergic and serotonergic neurotransmitter systems. Dorsal 
attention network prefrontal cortex (PFC) receives afferent connections from 
dopaminergic neurons within the ventral tegmental area and substantia nigra 
pars compacta387–389. PFC activity is modulated by multiple receptor 
subtypes389,390, including dopamine receptor 2 (D2R) which has been associated 
with cognitive flexibility and decision making213,215,391–393. PFC dopaminergic 
activity is associated with selective attention394–396 and working memory 
storage214,397–401, as well as facilitating top-down modulation of neural activity in 
early visual cortex395. Theoretical models propose that dopaminergic systems are 
involved in inhibitory control over bottom-up control over dorsal attention network 
by spatially tuning neuronal signals402–404, enhancing signal-to-noise ratios and 
suppressing competing information211,405,406. Polymorphisms in the catechol-O-
methyltransferase (COMT) gene, which regulate dopamine activation in PFC407–
409, have been associated with attentional control. COMT knockout mice show 
increased dopamine levels409,410. In humans, polymorphic differences have been 
associated with better attentional control performance and stronger 
neurophysiological responses in cingulate cortex212. PFC also receives afferent 
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connections from serotonergic neurons within the raphe nuclei411, and PFC 
activity is modulated by a dense distribution of serotonin receptors412. PFC 
serotonergic activity has been associated with executive functions413 and 
cognitive flexibility414. Polymorphisms in the serotonin transporter-linked 
polymorphic region (5-HTTLPR) gene, which regulate serotonin receptor density 
and neurotransmitter availability, have specifically been associated with 
attentional control216,218,415. In rat models, homozygous 5-HTTLPR knockout rats 
showed improved inhibitory control, whereas heterozygous knockout rats were 
similar to wild type rats216. In humans, polymorphic differences have been 
associated with better inhibitory control415 and working memory415 performance, 
and have shown differential effects on event-related potential measures 
associated with task performance218,415.  
An emerging field of research is investigating the impact of peripheral 
inflammation on complex cognitive functions governed at the molecular level, 
including synaptic plasticity, neurogenesis, and neuromodulation416,417. 
Conceptualized as “sickness behavior,” peripheral inflammation emerges from 
immune-mediated reorganization of homeostatic and behavioral priorities418,419. 
Increases in peripheral pro-inflammatory cytokine proteins likely activates a 
distributed network of brain cells that express cytokines and cytokine 
receptors418. Supporting this hypothesis, studies have demonstrated relationship 
between induced inflammatory responses and changes in cognitive function220–
223,420–422. Specifically, these studies have identified IL-6221,223,420–422, TNF-a222, 
and IL-8223 in mediating inflammation-related cognitive changes. Vaccine-
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induced peripheral inflammation is associated with altered substantia nigra 
activity221, which is associated with dopaminergic neurotransmitter system and 
dorsal attention network, and compensatory recruitment of dorsolateral PFC and 
anterior cingulate cortex. Critically, induced inflammatory responses were not 
associated with changes in cortisol levels223, potentially ruling out the contributing 
of psychosocial stress to inflammation-mediated cognitive changes. Thus, 
peripheral inflammatory activity may interact with dopaminergic neurotransmitter 
systems, resulting in altered attentional control function within the dorsal attention 
network. 
Biological Mechanisms of Cognitive Impairment 
 Understanding the underlying biological mechanisms of cancer- and 
chemotherapy-related cognitive impairment is critical to developing interventions 
and treatments for prevention and control efforts. Current models propose that 
cancer- and chemotherapy-related cognitive impairment is initiated by peripheral 
inflammation167. Here, hematological malignancy patients, receiving either 
chemotherapy or best supportive care, showed characteristically different 
longitudinal outcomes than healthy comparisons in electrophysiological 
measures of attentional control (i.e. N2pc and CDA amplitudes). These results 
suggest tumor biology and chemotherapy toxicity may affect downstream 
processes that specifically disrupts neural mechanisms of attentional control. To 
elucidate this putative mechanism, it is critical to demonstrate that peripheral 
inflammation induces a biochemical pathway that leads to the disruption of: (1) 
cortical structures within dorsal and ventral attention networks underlying 
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attentional control functions; (2) functional connectivity between cortical 
structures within attentional control networks; (3) neurotransmitter systems that 
modulate activity within attentional control networks; and (4) top-down and 
bottom-up control processes central to attentional control functions (Figure 1). In 
the following sections, patterns of results from both animal and human studies 
are presented to support evidence for this pathway. 
 Rodent models have shown evidence for a signaling cascade bridging 
systemic and neuro-inflammatory pathways423, providing a putative mechanism 
for peripheral inflammation to induce changes to neural structure and function. 
Current evidence suggests this periphery-to-brain pathway is mediated by NF-kB 
activity424–426, which degrades the integrity of the blood-brain barrier427–430, 
subsequently facilitating activation of cytokines produced by microglia and 
astrocytes431. In rodents, increases in circulating levels of the pro-inflammatory 
cytokine interleukin-6 (IL-6) have been associated with increases in hippocampal 
concentrations of IL-6432–434, IL-1b433, and TNF-a432,434. Furthermore, systemic 
injections of chemotherapeutic treatments for hematological malignancies, 
including cyclophosphamide, bortezomib, and methotrexate, have been 
associated with increases in pro-inflammatory cytokines in neural tissue131,139–141. 
These studies support the hypothesis that system inflammation induces 
microglial activation and subsequent neuroinflammatory pathways. 
 Rodent models have also shown evidence for a relationship between 
microglial activation and biochemical functions underlying cortical structure and 
function. Systemic injections of chemotherapeutic treatments for hematological 
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malignancies have been associated with neuronal degeneration113,114,122,123,125 
and apoptosis112,116,126,128,129, which is likely due to decreases in bone-derived 
neurotrophic factors (BDNF) observed in the same treatments 114,134. According 
to the inflammation-dopamine hypothesis, pro-inflammatory cytokines can alter 
neurotransmitter receptors191,419,435,436 and signaling435,436. Supporting this 
hypothesis, systemic treatment with chemotherapy has been associated with 
decreases in concentrations of glutamate130,132,133,135,437–444, dopamine136,137,434, 
and serotonin138,434,445. Importantly, these neurotransmitters have been 
associated with attentional control functions in both rodents and humans.  
 Although no direct translational links have been established between 
chemotherapy-related inflammation-mediated neurotransmitter dysfunction and 
attentional control dysfunction in cancer patients, current data supports this link. 
In humans, dopaminergic and serotonergic neurotransmitter systems have been 
associated with functional activity within the dorsal and ventral attention 
networks. Likewise, cancer- and chemotherapy-related changes in cortical 
structure and function have been demonstrated in dorsal and ventral attention 
networks. Specific regions impaired within the dorsal attention network include: 
SFG52,189,446–449, MFG52,96,175,177,184,186,187,189,446–451, IPS96,175,177,187,446,447,449, 
STG96,184,189,447,448, LOG446,447,450, postCing446; specific regions impaired within 
the ventral attention network include: SMA/Cingulate52,96,175,177,184,186,450,451, 
preCG96,184,187,189,448,450, postCG96,184,447,449,451, SPL96,184,187,446,447,449, CUN96,447, 
IFG96,175,177,184,186,187,446–448,451, LG/FG446. These results indicate potential to find a 
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relationship between inflammation-mediated neurotransmitter dysfunction and 
attentional control network dysfunction in human cancer studies. 
 Together, this translational research program requires further study to 
elucidate the link between peripheral inflammation and attentional control 
impairment in both human and non-human models. In rodent models, future 
studies should develop neuroimaging tools to study cortical networks involved in 
attentional control; in particular, cognitive electrophysiology measures similar to 
what was developed here would allow further study of task-related neural activity. 
In human models, future studies should incorporate methodologies that measure 
neurotransmitter concentrations and function; in particular, imaging modalities 
such as magnetic resonance spectroscopy (MRS) would allow imaging of 
neurotransmitter concentrations in dorsal and ventral attention networks. 
Furthermore, previous studies reviewed here should be replicated in addition to 
appending these proposed measures into study protocols to confirm and extend 
findings. 
Limitations of Current Study 
 This study was limited by a small sample size, due primarily to the 
experimental nature of the design. Study group sample sizes (n=15) were chosen 
to collect pilot data to determine the feasibility of study methods and obtain 
descriptive statistics to conduct power analysis to inform future large-scale 
confirmatory studies. This study was successful in both regards: I successfully 
collected proposed data from all three study groups, demonstrating study 
feasibility, and I was able to identify several key measures that hold promise for 
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future large-scale confirmatory analyses. Furthermore, I obtained important 
attrition data across groups, allowing for appropriate sample size adjustments 
across groups to increase the likelihood of achieving sufficient power in larger 
studies. Thus, although initially small sample sizes were further reduced by 
patient dropout, the study goals were achieved by obtaining important outcome 
measure and attrition data. 
 Multiple hematological malignancies were studied here. In conjunction 
with the small sample size noted above, I was unable to evaluate potential 
effects of cancer pathophysiology on outcome measures. Although differences in 
cognitive function across groups are foreseeable, given differences in 
hematopoietic lineages affected and tumor microenvironments, this question 
remains unexplored and in need of further study. Future large-scale studies may 
focus on a single sub-type of hematological malignancy or include cancer 
diagnosis as a model factor. Studies implementing the former strategy would be 
limited by small sample sizes, but would have a more pure disease-specific 
sample; studies implementing the latter strategy would be more successful in 
recruiting large sample sizes, but would have to rely on appropriate modeling 
procedures to separate disease-specific factors. Similar to the problem of 
enrolling multiple hematological malignancies, multiple chemotherapy protocols 
and agents were used in the chemotherapy group. This limitation precludes 
evaluating chemotherapy agent-specific effects on outcome measures presented 
here. Thus, future studies would benefit from more controlled studies of cancer- 
and chemotherapy-related effects. 
 115 
 Along similar lines, an important goal for future studies in the literature, 
including the current dissertation research, would be to determine how different 
cancer types across solid and liquid malignancies – and their interaction with 
chemotherapy agents – affects cognitive function. One important distinction 
between cancer pathophysiology is the emergence of the tumor 
microenvironment, in particular the positive feedback loop induced by the 
inflammation-mediated immune response. For example, inflammation is 
generally more pronounced in earlier stages of liquid tumors compared to solid 
tumors, whereas chemotherapy-induced changes in inflammation are more 
pronounced in solid tumors than in liquid tumors. Understanding the relationship 
between cancer type, chemotherapy toxicity, inflammation, and cognitive 
impairment is critical to mapping out associated changes in activities of daily 
living. 
 Due to patient characteristics, time constraints, and technical difficulties, 
completion rates of the driving simulation study were lower than data collection 
elements from other measures. As a result, these data were assessed using an 
analytic routine that differed from the rest of the study. Thus, this study was 
unable to evaluate separable effects of cancer and chemotherapy on 
electrophysiological and driving performance outcomes. Nevertheless, I obtained 
useful data that demonstrated marginally significant effects of cancer status on 
behavioral and electrophysiological measures of information processing capacity. 
In designing future studies, time limitations of the patient should be taken into 
consideration so that driving simulation studies are more complete. This 
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proposed change would result in one of two future directions: (1) reduce the 
number of cognitive and electrophysiological measures to allow for more time to 
complete driving simulation; or (2) conduct separate driving simulation studies 
that can focus more on driving performance measures and outcomes. In the 
former case, these studies would be well-suited to develop translational research 
programs aimed at understanding the relationship between cancer- and 
chemotherapy-related cognitive changes and driving performance – an 
instrumental activity of daily living; in the latter case, these studies would be well-
suited for extending these pilot findings into future driving studies that utilize on-
road technologies to record driving performance in the wild and monitor cancer- 
and chemotherapy-related changes in the prevalence of real-world hazardous 
events. 
 This study did not include a subjective measure of cognitive performance. 
Current evidence is controversial regarding the relationship between subjective 
and object assessments of cognitive performance. While some studies have 
found that complaints of cognitive dysfunction are accompanied with impairments 
in objective cognitive performance, other studies have failed to observe this 
relationship, instead finding that subjective cognitive function is better predicted 
by psychosocial status. Thus, this study was unable to contribute to this growing 
debate regarding the external validity of cross-platform tools. 
 Changes in electrophysiological biomarkers of attentional control function 
across study groups and assessments failed to match a priori predictions, 
resulting in a failure to accept both the null hypothesis and alternative hypothesis. 
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Nevertheless, these effects continue to support cancer- and chemotherapy-
related changes in attentional control function. Without MRI measures to map out 
concurrent changes in cortical structure and function, it is difficult to contextualize 
these unpredicted changes within the theoretical framework of attentional control 
network activity. Future studies should include MRI measures to better 
understand how cancer- and chemotherapy-related changes may be related to 
changes in attentional control network activity. 
Conclusions 
 A growing body of literature suggests cancer patients are susceptible to 
cognitive impairment due to factors related to tumor biology and chemotherapy 
toxicity, in addition to concurrent demographic and psychosocial factors that 
affect quality of life. This dissertation research sought to better understand the 
neural mechanisms of cancer- and chemotherapy-related cognitive impairment 
by developing an cognitive electrophysiology toolbox designed to dissect core 
attentional control functions that may explain broad patterns of cognitive 
impairment. These tools, which included laboratory implemented computer-
based experimental psychology tasks and driving simulations, were implemented 
in a longitudinal study design that investigated recently diagnosed hematological 
malignancy patients prior to starting chemotherapy, and following one-month and 
three-months of chemotherapy. Comparison groups included hematological 
malignancy patients receiving best support care or no treatment, and 
demographically-matched healthy controls. Reliable changes were noted in 
across laboratory measures, providing novel behavioral and neural evidence for 
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cancer- and chemotherapy-related impairments in attentional control function, 
and a promising translational research program for investigating the impact of 
attentional control dysfunction on simulated driving performance. Furthermore, 
laboratory measures correlated with performance on neuropsychological tests 
selected to probe similar attentional control functions. 
 There are several opportunities for future study. First, a large-scale 
confirmatory study is necessary to prove out the pattern of findings shown here. 
Second, additional neuroimaging methodologies (e.g. MRI) is needed to identify 
how electrophysiological patterns reported here are related to pathology in 
cortical structure and function. For example, cognitive aging literature suggests a 
posterior-to-anterior shift in neural activity is a hallmark of the aging brain; in 
future studies, it is important to determine whether similar shifts in cancer- and 
chemotherapy-related cognitive impairment contributes to changes in 
electrophysiological patterns shown here. Third, mechanisms of impairment in 
attentional control function should be proved out to identify key prevention and 
intervention strategies. As discussed in the Biological Mechanisms section, 
leading theories suggest peripheral inflammation induced by tumor biology and 
chemotherapy toxicity activates a signaling cascade, resulting in 
neuroinflammatory responses that affect neuronal signaling and structural 
integrity. Biomarkers for these biochemical processes should be incorporated 
into future human studies, and electrophysiological measures should to be 
developed for future animal studies to bridge this translational gap. Finally, the 
relationship between cognitive impairment and driving performance in cancer 
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patients is entirely unexplored. Future studies should focus on developing 
research programs aimed at identifying driving behaviors that are particularly 
sensitive to changes in attentional control function. 
 In conclusion, this dissertation research offers a key theoretical 
contribution to the underlying cognitive and neural mechanisms of cancer- and 
chemotherapy-related cognitive impairment. Paradigms developed here provide 
a platform for better understanding the relationship between chemotherapy-
induced neurotoxicity reported in animal studies and patterns of cognitive 
impairment reported in human studies. As cancer survivor populations continue 
to grow with improving treatment outcomes, it is critical to ensure the long-term 
quality of life of these patients. Addressing the underlying impairments in 




CHARACTERISTIC CTX+ CTX- HC 
Demographics    
Age 59.3 (15.2) 63.2 (10.9) 60.0 (16.5) 
Gender (Males) 8 (53%) 6 (40%) 7 (47%) 
Education (Years) 13.9 (1.7) 13.5 (1.3) 14.3 (1.6) 
Handedness (% Right) 11 (85%) 13 (93%) 12 (80%) 
Race (White) 15 (100%) 14 (93%) 15 (100%) 
Marital Status (Married) 11 (73%) 10 (67%) 8 (53%) 
General Function    
MMSE 29.5 (.7) 29.0 (1.4) 29.3 (1.6) 
Vision (% Normal) 5 (36%) 5 (36%) 4 (29%) 
Diagnosis    
NHL 10 (67%) 6 (40%)  
MDS 1 (7%) 6 (40%)  
AML 3 (20%) -  
CLL - 2 (13%)  
ALL 1 (7%) -  
MM - 1 (7%)  
 
Table 1. Patient Characteristics.  
Continuous data are presented as means and standard deviations: M (SD); 
Categorical data are presented as frequencies and percentatges: N (%). (Ctx+ = 
Chemotherapy patient group; Ctx- = non-chemotherapy patient group; HC = 
healthy control group; MMSE = Mini-Mental Status Examination; NHL = non-
Hodgkin lymphoma; MDS = myelodysplastic syndrome; AML = acute myeloid 
leukemia; CLL=chronic lymphocytic leukemia; ALL = acute lymphoblastic 





BASELINE QUALITY OF LIFE 
Measure Ctx+ Ctx- HC 
SF-36 N=10 N=10 N=14 
Gen Health 67.5±28.0 61.0±33.7 89.6±12.0 
Physical F 35.0±37.6 70.0±43.8 82.1±31.7 
Emotion F 62.5±30.0 75.0±19.5 87.5±4.9 
Social F 57.8±32.4 66.0±29.4 79.3±19.2 
Physical R 63.3±42.9 86.7±32.2 88.1±21.1 
Emotion R 39.2±24.4 52.5±23.5 65.4±15.2 
Fatigue 78.0±11.7 83.2±9.8 82.3±13.7 
Pain 51.0±27.9 55.5±20.2 73.9±19.1 
 
Table 2. Baseline Quality of Life.  
Means ± standard deviations for raw quality of life data. (Ctx+ = Chemotherapy 











BASELINE NEUROCOGNITIVE PERFORMANCE 
Measure Ctx+ Ctx- HC 
TMT N=14 N=14 N=15 
TMT-A 31.9±14.6 27.6±8.4 28.5±11.5 
TMT-B 95.4±78.8 68.6±20.2 69.0±38.3 
STROOP N=14 N=14 N=15 
Stroop-W 91.4±13.4 91.0±12.4 95.5±17.5 
Stroop-C 64.1±12.9 71.7±14.6 71.5±13.7 
Stroop-CW 27.7±12.6 34.0±10.5 37.1±14.0 
Stroop-I 9.7±10.5 5.8±10.9 3.6±11.4 
PASAT N=10 N=13 N=15 
Attempted 20.3±6.8 24.0±4.8 26.6±8.1 
Correct 17.9±7.1 21.6±5.3 23.9±8.5 
UFOV N=9 N=13 N=15 
Subtest 3 190.3±132.2 123.7±68.7 129.9±117.9 
 
Table 3. Baseline Neurocognitive Function.  
Means ± standard deviations for raw neurocognitive data. (Ctx+ = Chemotherapy 





BASELINE COGNITIVE ELECTROPHYSIOLOGY 
Measure Ctx+ Ctx- HC 
CAPTURE TASK    
Behavior N=9 N=14 N=15 
Neutral RT .79±.11 .87±.15 .89±.20 
Singleton RT .77±.10 .87±.16 .87±.20 
Contingent RT .81±.11 .91±.16 .94±.20 
Singleton d’ -.14±.09 -.01±.12 -.10±.15 
Contingent d’ .08±.13 .22±.19 .22±.16 
Cont-Sing d’ .24±.15 .24±.22 .33±.17 
Electrophysiology N=8 N=14 N=15 
Singleton N2pc -.50±.40 -.41±.88 .08±.28 
Contingent N2pc -1.0±.65 -.88±1.01 -.45±.49 
Difference N2pc -.50±.56 -.47±.35 -.52±.42 
FILTER TASK    
Behavior N=9 N=13 N=14 
Load-1 Accuracy .86±.08 .92±.07 .89±.12 
Load-3 Accuracy .62±.08 .67±.09 .70±.13 
Filter-1 Accuracy .86±.08 .91±.06 .88±.12 
Filter-3 Accuracy .61±.09 .63±.09 .67±.11 
Load Effect .16±.06 .15±.05 .12±.07 
Filter Effect .001±.02 .003±.02 .006±.02 
Electrophysiology N=8 N=12 N=14 
Load-1 CDA .07±.28 -.13±.47 -.21±.47 
Load-3 CDA -.69±.68 -.86±.77 -.92±.60 
Filter-1 CDA -.27±.37 -.35±.36 -.27±.27 
Filter-3 CDA -.56±.30 -.93±.73 -.83±.66 
Load Effect -.76±.80 -.73±.77 -.71±.78 
Filter Effect -.35±.21 -.21±.64 -.06±.47 
 
Table 4. Baseline Cognitive Electrophysiology.  
Means ± standard deviations for raw cognitive electrophysiology data. (Ctx+ = 
Chemotherapy patient group; Ctx- = non-chemotherapy patient group; HC = 
healthy control group). 
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 Ctx+ Group Ctx- Group HC Group 
Measure T1 T2 T3 T1 T2 T3 T1 T2 T3 
SF-36          
GenH 71.1±7.7 68.3±8.2 52.7±7.9 61.7±7.9 63.8±8.0 68.5±8.0 88.3±7.1 88.7±7.2 88.4±7.2 
Phys-F 33.7±10.9 31.8±13.5 26.0±12.1 68.5±11.1 64.9±11.6 63.5±11.5 81.9±9.5 91.4±10.1 94.4±10.4 
Emot-F 63.6±5.7 62.9±7.2 62.3±6.3 75.3±5.8 82.1±6.0 80.7±6.0 87.3±4.9 84.3±5.2 85.4±5.4 
Soc-F 59.0±7.1 75.8±8.0 66.7±7.5 68.0±7.2 71.0±7.4 76.2±7.3 77.3±6.3 79.5±6.5 77.7±6.6 
Phys-R 65.1±10.9 71.8±13.5 63.1±12.1 89.5±11.1 86.8±11.6 86.8±11.5 87.5±9.5 85.7±10.0 78.7±10.4 
Emot-R 42.8±7.0 46.7±7.8 35.2±7.3 49.7±7.1 54.2±7.3 57.6±7.2 64.8±6.3 69.7±6.4 66.3±6.5 
Fatigue 79.2±3.4 87.2±3.9 83.8±3.6 83.8±3.4 84.4±3.5 88.3±3.5 82.0±3.0 82.4±3.1 84.3±3.2 
Pain 51.5±6.3 52.8±6.9 41.4±6.6 53.8±6.4 54.0±6.6 52.7±6.5 73.8±5.7 73.8±5.9 74.9±5.9 
 
Table 5. Quality of Life LSM.  
Means and standard errors for least squared mean model parameters from full 
mixture model. (Ctx+ = Chemotherapy patient group; Ctx- = non-chemotherapy 






 Ctx+ Group Ctx- Group HC Group 
Measure T1 T2 T3 T1 T2 T3 T1 T2 T3 
TMT          
TMT-A 32.0±2.5 26.9±2.8 27.5±2.9 27.3±2.5 22.8±2.6 27.2±2.7 28.2±2.3 23.6±2.4 22.8±2.5 
TMT-B 96.1±11.8 71.2±12.7 67.2±13.0 67.0±11.6 69.7±12.1 55.8±12.3 68.0±11.1 71.2±11.4 61.0±11.7 
STROOP          
Stroop-W 92.6±3.9 100.4±4.2 100.7±4.3 91.5±3.8 95.9±4.0 97.0±4.1 95.6±3.6 101.0±3.7 99.2±3.8 
Stroop-C 64.8±3.2 68.0±3.5 67.6±3.6 71.2±3.2 70.6±3.4 75.8±3.5 72.4±3.0 73.8±3.1 74.0±3.1 
StroopCW 27.3±3.0 31.0±3.4 36.7±3.5 34.3±3.0 39.7±3.3 40.8±3.4 37.5±2.8 43.6±3.0 45.9±3.0 
Stroop-I 10.5±2.6 9.0±3.0 3.2±3.2 5.4±2.6 1.0±2.9 1.9±3.1 3.6±2.4 -1.1±2.6 -3.6±2.7 
PASAT          
Attempted 20.3±2.3 20.7±2.4 24.2±2.4 24.0±2.1 25.4±2.1 23.7±2.1 26.7±1.9 28.0±1.9 28.6±1.9 
UFOV          
Subtest 3 194.0±26.0 108.4±27.3 98.4±29.1 119.6±21.8 108.4±27.3 121.1±24.4 127.9±20.1 94.5±21.5 92.2±22.3 
 
Table 6. Neurocognitive LSM.  
Means and standard errors for least squared mean model parameters from full 
mixture model. (Ctx+ = Chemotherapy patient group; Ctx- = non-chemotherapy 





 Ctx+ Group Ctx- Group HC Group 
Measure T1 T2 T3 T1 T2 T3 T1 T2 T3 
CAPTURE TASK          
Behavior          
Neutral RT .81±.04 .76±.04 .74±.04 .84±.03 .79±.03 .77±.03 .89±.03 .79±.03 .89±.03 
Singleton RT .78±.04 .75±.04 .73±.04 .84±.03 .80±.03 .78±.03 .87±.03 .79±.03 .79±.03 
Contingent RT .82±.04 .78±.04 .76±.04 .88±.03 .82±.03 .80±.03 .94±.03 .84±.03 .81±.03 
Singleton d’ -.14±.05 -.04±.05 -.07±.05 -.01±.04 .01±.04 .06±.05 -.10±.04 .03±.04 -.003±.04 
Contingent d’ .08±.06 .19±.06 .14±.06 .23±.05 .19±.06 .25±.06 .22±.05 .28±.05 .17±.05 
Cont-Sing d’ .24±.07 .24±.07 .21±.07 .25±.06 .18±.06 .18±.06 .33±.05 .26±.06 .17±.06 
Electrophysiology          
Singleton N2pc -.45±.24 -.27±.24 -.23±.25 -.44±.19 -.46±.22 -.60±.22 .07±.18 -.43±.21 -.58±.21 
Contingent N2pc -.96±.28 .53±.28 -.59±.28 -.94±.22 -1.0±.25 -.64±.25 -.48±.21 -.84±.24 -1.14±.24 
Difference N2pc -.50±.26 -.27±.26 -.37±.26 -.50±.20 -.55±.23 -.04±.23 -.54±.19 -.40±.22 -.56±.22 
FILTER TASK          
Behavior          
Load-1 Accuracy .86±.03 .92±.03 .95±.03 .91±.03 .91±.03 .91±.03 .89±.03 .89±.03 .90±.03 
Load-3 Accuracy .62±.04 .72±.04 .72±.02 .67±.03 .67±.03 .69±.03 .70±.03 .69±.03 .71±.03 
Filter-1 Accuracy .86±.03 .93±.03 .94±.03 .91±.03 .88±.03 .92±.03 .88±.03 .89±.03 .90±.03 
Filter-3 Accuracy .61±.03 .66±.03 .69±.03 .63±.03 .66±.03 .64±.03 .67±.03 .67±.03 .70±.03 
Load Effect .16±.02 .12±.02 .14±.02 .15±.02 .16±.02 .15±.02 .12±.02 .13±.02 .11±.02 
Filter Effect .001±.01 -.01±.01 .01±.01 .004±.01 .02±.01 -.004±.01 .01±.01 .004±.01 -.002±.01 
Electrophysiology          
Load-1 CDA .05±.17 -.30±.17 -.19±.17 -.16±.14 .03±.16 -.48±.16 -.21±.13 -.22±.15 -.08±.15 
Load-3 CDA -.64±.26 -1.01±.26 -1.01±.26 -.93±.21 -.86±.23 -.83±.25 -.92±.20 -.75±.22 -.96±.23 
Filter-1 CDA -.25±.17 -.31±.17 -.75±.17 -.35±.14 -.40±.15 -.72±.16 -.26±.13 -.34±.15 -.34±.15 
Filter-3 CDA -.52±.30 -1.14±.29 -.81±.30 -.96±.25 -.73±.27 -1.13±.28 -.81±.23 -.72±.25 -.63±.26 
Load Effect -.76±.25 -.65±.25 -.81±.25 -.77±.20 -.92±.22 -.37±.24 -.71±.19 -.53±.21 -.90±.22 
Filter Effect -.33±.17 .00±.16 -.55±.17 -.21±.14 -.44±.15 -.23±.16 -.05±.13 -.10±.14 -.25±.15 
 
Table 7. Cognitive Electrophysiology LSM.  
Means and standard errors for least squared mean model parameters from full 
mixture model. (Ctx+ = Chemotherapy patient group; Ctx- = non-chemotherapy 






































































































































































































































































































































































































































































































































































































































































































































































Table 11. Matrix of correlations between neurocognitive and behavioral 




















































































































































































































































































































































































































Table 13. Matrix of correlations between behavioral and neural measures 










Figure 2. Computer-Based Cognitive Tasks.  
(A) Trial structure sequence and cue conditions for the capture task. Participants 
searched for and responded to the direction of the red “C” that could be 
presented in any one of placeholders in the search display. Prior to search 
display presentation, a task-irrelevant cue was presented around a single square 
placeholder. For 50% of trials, no placeholder was cued (neutral condition); the 
remaining 50% of trials were divided equally between a single cue that was either 
the same color as the target (contingent condition) or different color than the 
target (singleton condition). (B) Trials structure and memory conditions for the 
filter task. Participants were cued to remember the orientation of red memory 
items presented on either the left or right side of the screen, depending on cue 
direction. After a short delay, participants were instructed to indicate whether a 
single test item was the same or different orientation as the item in the same 
probed location during the memory display. Participants remembered either 1 
(Load-1 condition) or 3 (Load-3 condition) memory items. Participants were 
instructed to ignore any non-red items, which were present during half of the 
trials among either 1 (Filter-1) or 3 (Filter-3) memory items. 
 
Filter Task Displays
ITI Task-Irrelevant Cue ISI Search Display





















Figure 3. Simulator Task.  
(A) Participants completed simulated driving scenarios in SENSEI (Simulator for 
Ergonomic, Neuroscience, Safety, Engineering, and Innovation). (B) Participants 
completed visual search tasks by responding with the direction of a red target 
stimulus presented among black distractors. Visual search displays were 
presented on the center display in SENSEI. During the driving (shown in B) 
condition, visual search stimuli were presented against the simulated 
background. During the baseline condition, stimuli were presented against a 
black background. 
  
SENSEI Visual Search Display





Figure 4. Electrophysiological Waveforms.  
Grand averaged waveforms are presented for cognitive electrophysiology 
measures. EEG amplitudes (in microvolts) are plotted as a function of time (in 
milliseconds), where time=0 corresponds to stimulus onset. (A) In the capture 
task, a large negative deflection in EEG amplitude emerges approximately 200 
milliseconds following cue onset. This large negative deflection corresponds to 
the N2pc component, which was present for the both singleton (blue) and 
contingent (red) conditions. Average N2pc amplitudes were estimated within the 
gray window. (B) In the filter task, sustained negative potentials were observed in 
EEG activity across the entire delay period, which emerged approximately 300 
milliseconds following presentation of the memory display. This sustained 
negativity corresponds to the CDA component, which was present for the load-1 
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Figure 5. Quality of Life LSM.  
Plotted means for least squared mean model parameters from full mixture model. 
Only outcome measures showing group or group-by-time interactions at p<.20 
are displayed. (Ctx+ = Chemotherapy patient group; Ctx- = non-chemotherapy 


















































































Figure 6. Neurocognitive LSM.  
Plotted means for least squared mean model parameters from full mixture model. 
Only outcome measures showing group or group-by-time interactions at p<.20 
are displayed. (Ctx+ = Chemotherapy patient group; Ctx- = non-chemotherapy 
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Figure 7. Cognitive Electrophysiology LSM.  
Plotted means for least squared mean model parameters from full mixture model. 
Only outcome measures showing group or group-by-time interactions at p<.20 
are displayed. (Ctx+ = Chemotherapy patient group; Ctx- = non-chemotherapy 
patient group; HC = healthy control group; T1=baseline; T2=one-month followup; 





















































































Figure 8. EFRP Results.  
(A,B) EFRP activity was measured by estimating mean EEG amplitude as a 
function of time relative to saccade offset (time=0). P1 activity (gray boxes) 
emerged approximately 100 milliseconds after saccade offset. (A) EFRP activity 
is plotted separately for healthy control (HC; blue line) drivers and drivers 
diagnosed with a hematological malignancy (HM; red line). (B) Drivers were split 
into two groups based on differences in visual search response time (RT) 
between driving and baseline conditions. EFRP activity is plotted separately for 
drivers showing smaller (low cost; black line) and larger (high cost; gray line) RT 
differences. (C, D) P1 amplitude was estimated as mean EFRP activity during 
the P1 time window (gray boxes in A, B). (C) P1 amplitudes were larger for HC 
(blue) drivers compared to HM drivers (red; p=.18). (D) P1 amplitudes were 
larger for drivers with low RT costs (black) compared to drivers with high RT 






























































Figure 9. Venn diagram of empirical patterns observed in neurocognitive data.  
Three empirical patterns are highlighted: (1) Chemotherapy (red); (2) Cancer 
(blue); (3) Disease Severity (green). Archetypes for each empirical pattern were 
provided as plot insets, with individual predictions for Ctx+ (red line), Ctx- (blue 
line), and HC (black line) groups. Outcome measures are presented within 
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